

TEKLA HEALTHCARE INVESTORS  
Form N-PX  
August 20, 2018

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**

OMB APPROVAL  
OMB Number: 3235-0582  
Expires: March 31, 2021  
Estimated average burden  
hours per response.....7.2

Washington, D.C. 20549

**FORM N-PX**

**ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED  
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number 811- 04889

**Tekla Healthcare Investors**

(Exact name of registrant as specified in charter)

**100 Federal Street, 19th Floor, Boston, MA**  
(Address of principal executive offices)

**02110**  
(Zip code)

**Laura Woodward**

**Tekla Healthcare Investors**

**100 Federal Street, 19th Floor, Boston MA 02110**

(Name and address of agent for service)

Registrant's telephone number, including area code: **617-772-8500**

Date of fiscal year end: **September 30**

## Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Date of reporting period: **7/1/17-6/30/18**

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss.239.24 and 274.5 of this chapter), to file reports with the Commission, not later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

---

**Item 1. Proxy Voting Record.**

---

### Vote Summary

#### ABBOTT LABORATORIES

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 002824100   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ABT         | <b>Meeting Date</b> | 27-Apr-2018 |
| <b>Record Date</b>   | 28-Feb-2018 |                     |             |

| Item | Proposal                                                        | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                        | Management  |      |                        |
| 1    | R.J. Alpern                                                     |             | For  | For                    |
| 2    | R.S. Austin                                                     |             | For  | For                    |
| 3    | S.E. Blount                                                     |             | For  | For                    |
| 4    | E.M. Liddy                                                      |             | For  | For                    |
| 5    | N. McKinstry                                                    |             | For  | For                    |
| 6    | P.N. Novakovic                                                  |             | For  | For                    |
| 7    | W.A. Osborn                                                     |             | For  | For                    |
| 8    | S.C. Scott III                                                  |             | For  | For                    |
| 9    | D.J. Starks                                                     |             | For  | For                    |
| 10   | J.G. Stratton                                                   |             | For  | For                    |
| 11   | G.F. Tilton                                                     |             | For  | For                    |
| 12   | M.D. White                                                      |             | For  | For                    |
| 2.   | Ratification of Ernst & Young LLP as Auditors                   | Management  | For  | For                    |
| 3.   | Say on Pay - An Advisory Vote to Approve Executive Compensation | Management  | For  | For                    |
| 4.   | Shareholder Proposal - Independent Board Chairman               | Shareholder | For  | Against                |

#### ABBVIE INC.

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 00287Y109   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ABBV        | <b>Meeting Date</b> | 04-May-2018 |
| <b>Record Date</b>   | 07-Mar-2018 |                     |             |

| Item | Proposal                                                                                                   | Proposed by | Vote   | For/Against Management |
|------|------------------------------------------------------------------------------------------------------------|-------------|--------|------------------------|
| 1.   | DIRECTOR                                                                                                   | Management  |        |                        |
| 1    | Roxanne S. Austin                                                                                          |             | For    | For                    |
| 2    | Richard A. Gonzalez                                                                                        |             | For    | For                    |
| 3    | Rebecca B. Roberts                                                                                         |             | For    | For                    |
| 4    | Glenn F. Tilton                                                                                            |             | For    | For                    |
| 2.   | Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2018       | Management  | For    | For                    |
| 3.   | Say on Pay - An advisory vote on the approval of executive compensation                                    | Management  | For    | For                    |
| 4.   | Say When on Pay - An advisory vote on the frequency of the advisory vote to approve executive compensation | Management  | 1 Year | For                    |
| 5.   |                                                                                                            | Management  | For    | For                    |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|    |                                                                                                                                |             |         |         |
|----|--------------------------------------------------------------------------------------------------------------------------------|-------------|---------|---------|
|    | Approval of a management proposal regarding amendment of the certificate of incorporation for the annual election of directors |             |         |         |
| 6. | Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting    | Management  | For     | For     |
| 7. | Stockholder Proposal - to Issue an Annual Report on Lobbying                                                                   | Shareholder | Against | For     |
| 8. | Stockholder Proposal - to Separate Chair and CEO                                                                               | Shareholder | For     | Against |
| 9. | Stockholder Proposal - to Issue an Annual Compensation Committee Report on Drug Pricing                                        | Shareholder | Against | For     |

---

AC IMMUNE SA

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | H00263105   | <b>Meeting Type</b> | Special     |
| <b>Ticker Symbol</b> | ACIU        | <b>Meeting Date</b> | 27-Apr-2018 |
| <b>Record Date</b>   | 13-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                                                    | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | In the event that at the Extraordinary Shareholders Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors | Management  | For  | N/A                    |
| 2.A  | Election of Douglas Williams as Member to the Board of Directors                                                                                                                                                                                                                                                                                            | Management  | For  | N/A                    |
| 2.B  | Election of Douglas Williams to the Compensation, Nomination & Corporate Governance Committee                                                                                                                                                                                                                                                               | Management  | For  | N/A                    |
| 3.a  | Vote on Total Non-Performance-Related Compensation for the new Member of the Board of Directors from 27 April 2018 to 30 June 2018                                                                                                                                                                                                                          | Management  | For  | N/A                    |
| 3.b  | Vote on Equity for the new Member of the Board of Directors                                                                                                                                                                                                                                                                                                 | Management  | For  | N/A                    |
| 4.a  | Share Capital Increase for Institutional Investors                                                                                                                                                                                                                                                                                                          | Management  | For  | N/A                    |
| 4.b  | Share Capital Increase for Current Shareholders                                                                                                                                                                                                                                                                                                             | Management  | For  | N/A                    |

## AC IMMUNE SA

|                                                   |                                  |                                      |                       |
|---------------------------------------------------|----------------------------------|--------------------------------------|-----------------------|
| <b>Security<br/>Ticker Symbol<br/>Record Date</b> | H00263105<br>ACIU<br>23-May-2018 | <b>Meeting Type<br/>Meeting Date</b> | Annual<br>06-Jul-2018 |
|---------------------------------------------------|----------------------------------|--------------------------------------|-----------------------|

| Item | Proposal                                                                                                                                                                                                                                                                                                                                        | Proposed<br>by | Vote | For/Against<br>Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------|---------------------------|
| A.   | In the event that at the Annual General Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors | Management     | For  | N/A                       |
| 1.   | Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2017                                                                                                                                                                                                      | Management     | For  | N/A                       |
| 2.   | Appropriation of Loss                                                                                                                                                                                                                                                                                                                           | Management     | For  | N/A                       |
| 3.   | Discharge of the Members of the Board of Directors and the Executive Committee                                                                                                                                                                                                                                                                  | Management     | For  | N/A                       |
| 4a.  | Vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2018 to 30 June 2019                                                                                                                                                                                                                       | Management     | For  | N/A                       |
| 4b.  | Vote on Equity for Members of the Board of Directors                                                                                                                                                                                                                                                                                            | Management     | For  | N/A                       |
| 4c.  | Vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2018 to 30 June 2019                                                                                                                                                                                                                      | Management     | For  | N/A                       |
| 4d.  | Vote on Total Variable Compensation for Members of the Executive Committee for the current year 2018                                                                                                                                                                                                                                            | Management     | For  | N/A                       |
| 4e.  | Vote on Equity for Members of the Executive Committee                                                                                                                                                                                                                                                                                           | Management     | For  | N/A                       |
| 5a.  | Re-election of Martin Velasco as member and Chairman of the Board of Directors                                                                                                                                                                                                                                                                  | Management     | For  | N/A                       |
| 5b.  | Re-election of Peter Bollmann as the Member of the Board                                                                                                                                                                                                                                                                                        | Management     | For  | N/A                       |
| 5c.  | Re-election of Friedrich von Bohlen as the Member of the Board                                                                                                                                                                                                                                                                                  | Management     | For  | N/A                       |
| 5d.  | Re-election of Andrea Pfeifer as the Member of the Board                                                                                                                                                                                                                                                                                        | Management     | For  | N/A                       |
| 5e.  | Re-election of Detlev Riesner as the Member of the Board including granting an exception to the age limit                                                                                                                                                                                                                                       | Management     | For  | N/A                       |
| 5f.  | Re-election of Tom Graney as the Member of the Board                                                                                                                                                                                                                                                                                            | Management     | For  | N/A                       |
| 5g.  | Re-election of Douglas Williams as the Member of the Board                                                                                                                                                                                                                                                                                      | Management     | For  | N/A                       |
| 5h.  | Election of Werner Lanthaler as the Member of the Board                                                                                                                                                                                                                                                                                         | Management     | For  | N/A                       |
| 6a.  | Re-election of Tom Graney to the Compensation, Nomination & Corporate Governance Committee                                                                                                                                                                                                                                                      | Management     | For  | N/A                       |
| 6b.  | Re-election of Martin Velasco to the Compensation, Nomination & Corporate Governance Committee                                                                                                                                                                                                                                                  | Management     | For  | N/A                       |
| 6c.  | Re-election of Doug Williams to the Compensation, Nomination & Corporate Governance Committee                                                                                                                                                                                                                                                   | Management     | For  | N/A                       |
| 7.   | Re-election of the independent proxy Bugnion Ballansat Ehrler, represented by Gerald Virieux, avocat, Geneva                                                                                                                                                                                                                                    | Management     | For  | N/A                       |
| 8.   | Election of the Auditors, PricewaterhouseCoopers SA, Pully                                                                                                                                                                                                                                                                                      | Management     | For  | N/A                       |
| 9a.  | Share Capital Increase for Institutional Investors                                                                                                                                                                                                                                                                                              | Management     | For  | N/A                       |
| 9b.  | Share Capital Increase for Current Shareholders                                                                                                                                                                                                                                                                                                 | Management     | For  | N/A                       |





**ACADIA HEALTHCARE COMPANY, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 00404A109   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ACHC        | <b>Meeting Date</b> | 03-May-2018 |
| <b>Record Date</b>   | 09-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                 | Proposed by | Vote | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.1  | Election of Director: E. Perot Bissell                                                                                                                   | Management  | For  | For                    |
| 1.2  | Election of Director: Vicky B. Gregg                                                                                                                     | Management  | For  | For                    |
| 2.   | Advisory vote on the compensation of the Company's named executive officers as presented in the Proxy Statement.                                         | Management  | For  | For                    |
| 3.   | Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**ACADIA PHARMACEUTICALS INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 004225108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ACAD        | <b>Meeting Date</b> | 06-Jun-2018 |
| <b>Record Date</b>   | 13-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                           | Proposed by | Vote | For/Against Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                                           | Management  |      |                        |
|      | 1 Julian Baker                                                                                                                                                                                                     |             | For  | For                    |
|      | 2 Stephen Biggar, M.D PhD                                                                                                                                                                                          |             | For  | For                    |
|      | 3 Daniel Soland                                                                                                                                                                                                    |             | For  | For                    |
| 2.   | To approve an amendment to our 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,700,000 shares. | Management  | For  | For                    |
| 3.   | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting.                                                                    | Management  | For  | For                    |
| 4.   | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.                                                                    | Management  | For  | For                    |

**ACCELERON PHARMA INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 00434H108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | XLRN        | <b>Meeting Date</b> | 06-Jun-2018 |
| <b>Record Date</b>   | 09-Apr-2018 |                     |             |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                                                                                                                                  | Proposed<br>by | Vote | For/Against<br>Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------|---------------------------|
| 1a.  | Election of Class II Director: Habib J. Dable                                                                                                             | Management     | For  | For                       |
| 1b.  | Election of Class II Director: Terrence C. Kearney                                                                                                        | Management     | For  | For                       |
| 1c.  | Election of Class II Director: Karen L. Smith, M.D., Ph.D.                                                                                                | Management     | For  | For                       |
| 2.   | To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the proxy statement.                    | Management     | For  | For                       |
| 3.   | To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management     | For  | For                       |

---

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**AKEBIA THERAPEUTICS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 00972D105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | AKBA        | <b>Meeting Date</b> | 14-Jun-2018 |
| <b>Record Date</b>   | 20-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                          | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                          | Management  |      |                        |
|      | 1 Michael D. Clayman                                                                                                                                              |             | For  | For                    |
|      | 2 Duane Nash                                                                                                                                                      |             | For  | For                    |
|      | 3 Ronald C. Renaud, Jr.                                                                                                                                           |             | For  | For                    |
|      | 4 John P. Butler                                                                                                                                                  |             | For  | For                    |
|      | 5 Muneer A. Satter                                                                                                                                                |             | For  | For                    |
|      | 6 Michael S. Wyzga                                                                                                                                                |             | For  | For                    |
| 2.   | Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**ALBIREO PHARMA INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 01345P106   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ALBO        | <b>Meeting Date</b> | 08-Jun-2018 |
| <b>Record Date</b>   | 18-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                | Management  |      |                        |
|      | 1 Ronald H.W. Cooper                                                                                                                                    |             | For  | For                    |
|      | 2 Anne Klibanski, M.D.                                                                                                                                  |             | For  | For                    |
|      | 3 Stephanie S. Okey, M.S.                                                                                                                               |             | For  | For                    |
| 2.   | To approve the Albireo Pharma, Inc. 2018 Equity Incentive Plan.                                                                                         | Management  | For  | For                    |
| 3.   | To approve the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan.                                                                                  | Management  | For  | For                    |
| 4.   | To ratify the appointment of Ernst & Young LLP as Albireo's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**ALDER BIOPHARMACEUTICALS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 014339105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ALDR        | <b>Meeting Date</b> | 23-May-2018 |
| <b>Record Date</b>   | 20-Apr-2018 |                     |             |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|----------|-------------|------|------------------------|
|------|----------|-------------|------|------------------------|

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|    |                                                                                                                                                                                                                          |            |     |     |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| 1. | DIRECTOR                                                                                                                                                                                                                 | Management |     |     |
|    | 1 Paul B. Cleveland                                                                                                                                                                                                      |            | For | For |
|    | 2 Stephen M. Dow                                                                                                                                                                                                         |            | For | For |
|    | 3 A. Bruce Montgomery                                                                                                                                                                                                    |            | For | For |
| 2. | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.                                                                          | Management | For | For |
| 3. | To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. | Management | For | For |

---

**ALEXION PHARMACEUTICALS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 015351109   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ALXN        | <b>Meeting Date</b> | 08-May-2018 |
| <b>Record Date</b>   | 12-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                            | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                            | Management  |      |                        |
| 1    | Felix J. Baker                                                                                                                                      |             | For  | For                    |
| 2    | David R. Brennan                                                                                                                                    |             | For  | For                    |
| 3    | Christopher J. Coughlin                                                                                                                             |             | For  | For                    |
| 4    | Deborah Dunsire                                                                                                                                     |             | For  | For                    |
| 5    | Paul A. Friedman                                                                                                                                    |             | For  | For                    |
| 6    | Ludwig N. Hantson                                                                                                                                   |             | For  | For                    |
| 7    | John T. Mollen                                                                                                                                      |             | For  | For                    |
| 8    | Francois Nader                                                                                                                                      |             | For  | For                    |
| 9    | Judith A. Reinsdorf                                                                                                                                 |             | For  | For                    |
| 10   | Andreas Rummelt                                                                                                                                     |             | For  | For                    |
| 2.   | Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm. | Management  | For  | For                    |
| 3.   | Approval of a non-binding advisory vote of the 2017 compensation paid to Alexion's named executive officers.                                        | Management  | For  | For                    |
| 4.   | To request the Board to require an independent Chairman.                                                                                            | Shareholder | For  | Against                |

**ALKERMES PLC**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | G01767105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ALKS        | <b>Meeting Date</b> | 23-May-2018 |
| <b>Record Date</b>   | 23-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                | Proposed by | Vote   | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------|------------------------|
| 1a.  | Election of Director: Floyd E. Bloom, M.D.                                                                                                                                                                                                                                                                              | Management  | For    | For                    |
| 1b.  | Election of Director: Nancy L. Snyderman, M.D.                                                                                                                                                                                                                                                                          | Management  | For    | For                    |
| 1c.  | Election of Director: Nancy Wysenski                                                                                                                                                                                                                                                                                    | Management  | For    | For                    |
| 2.   | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                           | Management  | For    | For                    |
| 3.   | To hold a non-binding, advisory vote, on the frequency of future advisory votes on the compensation paid to the Company's named executive officers.                                                                                                                                                                     | Management  | 1 Year | For                    |
| 4.   | To ratify, on a non-binding, advisory basis, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board of Directors to set the independent auditor and accounting firm's remuneration. | Management  | For    | For                    |
| 5.   | To approve the Alkermes plc 2018 Stock Option and Incentive plan.                                                                                                                                                                                                                                                       | Management  | For    | For                    |



Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

ALLERGAN PLC

|               |             |              |             |
|---------------|-------------|--------------|-------------|
| Security      | G0177J108   | Meeting Type | Annual      |
| Ticker Symbol | AGN         | Meeting Date | 02-May-2018 |
| Record Date   | 06-Mar-2018 |              |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                                  | Proposed by | Vote    | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1a.  | Election of Director: Nesli Basgoz, M.D.                                                                                                                                                                                                                                                                                                  | Management  | For     | For                    |
| 1b.  | Election of Director: Paul M. Bisaro                                                                                                                                                                                                                                                                                                      | Management  | For     | For                    |
| 1c.  | Election of Director: Joseph H. Boccuzzi                                                                                                                                                                                                                                                                                                  | Management  | For     | For                    |
| 1d.  | Election of Director: Christopher W. Bodine                                                                                                                                                                                                                                                                                               | Management  | For     | For                    |
| 1e.  | Election of Director: Adriane M. Brown                                                                                                                                                                                                                                                                                                    | Management  | For     | For                    |
| 1f.  | Election of Director: Christopher J. Coughlin                                                                                                                                                                                                                                                                                             | Management  | For     | For                    |
| 1g.  | Election of Director: Carol Anthony (John) Davidson                                                                                                                                                                                                                                                                                       | Management  | For     | For                    |
| 1h.  | Election of Director: Catherine M. Klema                                                                                                                                                                                                                                                                                                  | Management  | For     | For                    |
| 1i.  | Election of Director: Peter J. McDonnell, M.D.                                                                                                                                                                                                                                                                                            | Management  | For     | For                    |
| 1j.  | Election of Director: Patrick J. O. Sullivan                                                                                                                                                                                                                                                                                              | Management  | For     | For                    |
| 1k.  | Election of Director: Brenton L. Saunders                                                                                                                                                                                                                                                                                                 | Management  | For     | For                    |
| 1l.  | Election of Director: Fred G. Weiss                                                                                                                                                                                                                                                                                                       | Management  | For     | For                    |
| 2.   | To approve, in a non-binding vote, Named Executive Officer compensation.                                                                                                                                                                                                                                                                  | Management  | For     | For                    |
| 3.   | To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the Board of Directors, acting through its Audit and Compliance Committee, to determine PricewaterhouseCoopers LLP's remuneration. | Management  | For     | For                    |
| 4.   | To renew the authority of the directors of the Company (the Directors) to issue shares.                                                                                                                                                                                                                                                   | Management  | For     | For                    |
| 5A.  | To renew the authority of the Directors to issue shares for cash without first offering shares to existing shareholders.                                                                                                                                                                                                                  | Management  | For     | For                    |
| 5B.  | To authorize the Directors to allot new shares up to an additional 5% for cash in connection with an acquisition or other capital investment.                                                                                                                                                                                             | Management  | For     | For                    |
| 6.   | To consider a shareholder proposal requiring an independent Board Chairman, if properly presented at the meeting.                                                                                                                                                                                                                         | Shareholder | Against | For                    |

ALLIQUA BIOMEDICAL, INC.

|               |             |              |             |
|---------------|-------------|--------------|-------------|
| Security      | 019621200   | Meeting Type | Special     |
| Ticker Symbol | ALQA        | Meeting Date | 13-Sep-2017 |
| Record Date   | 26-Jul-2017 |              |             |

| Item | Proposal                                                                                                          | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | TO RATIFY THE FILING AND EFFECTIVENESS OF THE CERTIFICATE OF AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF | Management  | For  | For                    |

|                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                |            |     |     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| INCORPORATION FILED WITH THE SECRETARY OF STATE OF THE STATE OF DELAWARE ON MAY 6, 2016 AND THE INCREASE IN THE NUMBER OF SHARES OF AUTHORIZED COMMON STOCK EFFECTED THEREBY. |                                                                                                                                                                                                                                                                                                                                                                                |            |     |     |
| 2.                                                                                                                                                                            | TO APPROVE THE PROPOSAL TO AUTHORIZE THE COMPANY S BOARD OF DIRECTORS, IN ITS DISCRETION BUT PRIOR TO THE ANNUAL MEETING OF THE COMPANY S STOCKHOLDERS IN 2018, TO AMEND THE COMPANY S CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANY S COMMON STOCK, AT A RATIO IN THE RANGE OF ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL). | Management | For | For |
| 3.                                                                                                                                                                            | TO APPROVE AN ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF ANY OF THE FOREGOING PROPOSALS.                                                                                                                                                                                                    | Management | For | For |



**ALLIQUA BIOMEDICAL, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 019621309   | <b>Meeting Type</b> | Special     |
| <b>Ticker Symbol</b> | ALQA        | <b>Meeting Date</b> | 27-Apr-2018 |
| <b>Record Date</b>   | 23-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                              | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | A proposal to approve the Asset Purchase Agreement, the Asset Sale Transaction and the other transactions contemplated by the Asset Purchase Agreement ( the Asset Sale Proposal ).                                                   | Management  | For  | For                    |
| 2.   | A proposal to approve, on an advisory, non-binding basis, certain compensation that has, will or may be paid or become payable to the Company s named executive officers in connection with the asset sale ( the Advisory Proposal ). | Management  | For  | For                    |
| 3.   | A proposal to adjourn or postpone the Special Meeting of stockholders, if necessary or appropriate, for the purpose of soliciting additional votes for the approval of the Asset Sale Proposal ( the Adjournment Proposal ).          | Management  | For  | For                    |

**ALLIQUA BIOMEDICAL, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 019621309   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ALQA        | <b>Meeting Date</b> | 26-Jun-2018 |
| <b>Record Date</b>   | 03-May-2018 |                     |             |

| Item | Proposal                                                                                                                                         | Proposed by | Vote | For/Against Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                         | Management  |      |                        |
|      | 1 David Johnson                                                                                                                                  |             | For  | For                    |
|      | 2 Joseph Leone                                                                                                                                   |             | For  | For                    |
|      | 3 Gary Restani                                                                                                                                   |             | For  | For                    |
|      | 4 Jeffrey Sklar                                                                                                                                  |             | For  | For                    |
|      | 5 Mark Wagner                                                                                                                                    |             | For  | For                    |
| 2.   | Ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**ALNYLAM PHARMACEUTICALS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 02043Q107   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ALNY        | <b>Meeting Date</b> | 10-May-2018 |
| <b>Record Date</b>   | 15-Mar-2018 |                     |             |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                                                                                                                                                                   | Proposed<br>by | Vote | For/Against<br>Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------|---------------------------|
| 1a.  | Election of Class II Director: Dennis A. Ausiello, M.D.                                                                                                                                    | Management     | For  | For                       |
| 1b.  | Election of Class II Director: John K. Clarke                                                                                                                                              | Management     | For  | For                       |
| 1c.  | Election of Class II Director: Marsha H. Fanucci                                                                                                                                           | Management     | For  | For                       |
| 1d.  | Election of Class II Director: David E.I. Pyott                                                                                                                                            | Management     | For  | For                       |
| 2.   | To approve the 2018 Stock Incentive Plan.                                                                                                                                                  | Management     | For  | For                       |
| 3.   | To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.                                                                                        | Management     | For  | For                       |
| 4.   | To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2018. | Management     | For  | For                       |

**AMARIN CORPORATION PLC**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 023111206   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | AMRN        | <b>Meeting Date</b> | 14-May-2018 |
| <b>Record Date</b>   | 18-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                               | Proposed by | Vote | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | To re-elect Mr. John F. Thero as a director.                                                                                                                                                                                                                                                                                           | Management  | For  | For                    |
| 2.   | To re-elect Mr. Patrick J. O. Sullivan as a director.                                                                                                                                                                                                                                                                                  | Management  | For  | For                    |
| 3.   | To hold an advisory (non-binding) vote to approve the compensation of the Company's named executive officers as described in full in the accompanying Proxy Statement.                                                                                                                                                                 | Management  | For  | For                    |
| 4.   | To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors remuneration as described in the accompanying Proxy Statement. | Management  | For  | For                    |

**AMGEN INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 031162100   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | AMGN        | <b>Meeting Date</b> | 22-May-2018 |
| <b>Record Date</b>   | 23-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                | Proposed by | Vote    | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1a.  | Election of Director: Dr. Wanda M. Austin                                                                                                                                               | Management  | For     | For                    |
| 1b.  | Election of Director: Mr. Robert A. Bradway                                                                                                                                             | Management  | For     | For                    |
| 1c.  | Election of Director: Dr. Brian J. Druker                                                                                                                                               | Management  | For     | For                    |
| 1d.  | Election of Director: Mr. Robert A. Eckert                                                                                                                                              | Management  | For     | For                    |
| 1e.  | Election of Director: Mr. Greg C. Garland                                                                                                                                               | Management  | For     | For                    |
| 1f.  | Election of Director: Mr. Fred Hassan                                                                                                                                                   | Management  | For     | For                    |
| 1g.  | Election of Director: Dr. Rebecca M. Henderson                                                                                                                                          | Management  | For     | For                    |
| 1h.  | Election of Director: Mr. Frank C. Herringer                                                                                                                                            | Management  | For     | For                    |
| 1i.  | Election of Director: Mr. Charles M. Holley, Jr.                                                                                                                                        | Management  | For     | For                    |
| 1j.  | Election of Director: Dr. Tyler Jacks                                                                                                                                                   | Management  | For     | For                    |
| 1k.  | Election of Director: Ms. Ellen J. Kullman                                                                                                                                              | Management  | For     | For                    |
| 1l.  | Election of Director: Dr. Ronald D. Sugar                                                                                                                                               | Management  | For     | For                    |
| 1m.  | Election of Director: Dr. R. Sanders Williams                                                                                                                                           | Management  | For     | For                    |
| 2.   | Advisory vote to approve our executive compensation.                                                                                                                                    | Management  | For     | For                    |
| 3.   | To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2018.                                             | Management  | For     | For                    |
| 4.   | Stockholder proposal for an annual report on the extent to which risks related to public concern over drug pricing strategies are integrated into our executive incentive compensation. | Shareholder | Against | For                    |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

AMICUS THERAPEUTICS, INC.

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 03152W109   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | FOLD        | <b>Meeting Date</b> | 07-Jun-2018 |
| <b>Record Date</b>   | 16-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                    | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                                                    | Management  |      |                        |
|      | 1 Donald J. Hayden, Jr.                                                                                                                                                                                                     |             | For  | For                    |
|      | 2 Craig Wheeler                                                                                                                                                                                                             |             | For  | For                    |
| 2.   | Proposal to approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value \$0.01 per share, that we are authorized to issue from 250,000,000 to 500,000,000 | Management  | For  | For                    |
| 3.   | Approval of the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool                                                                                                                  | Management  | For  | For                    |
| 4.   | Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018                                                                     | Management  | For  | For                    |
| 5.   | Approval, on an advisory basis, the Company's executive compensation                                                                                                                                                        | Management  | For  | For                    |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

AMPHIVENA THERAPEUTICS, INC

|               |     |              |                 |
|---------------|-----|--------------|-----------------|
| Security      | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 20-Dec-2017     |
| Record Date   | N/A |              |                 |

| Item | Proposal                                                      | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------|-------------|------|------------------------|
| 1.   | Approval of Amended and Restated Certificate of Incorporation | Management  | For  | For                    |
| 2.   | Approval of Bridge Loan and Waiver of Right of First Offer    | Management  | For  | For                    |
| 3.   | Omnibus Resolutions                                           | Management  | For  | For                    |

ANTHEM, INC.

|               |             |              |             |
|---------------|-------------|--------------|-------------|
| Security      | 036752103   | Meeting Type | Annual      |
| Ticker Symbol | ANTM        | Meeting Date | 16-May-2018 |
| Record Date   | 09-Mar-2018 |              |             |

| Item | Proposal                                                                                                                                                               | Proposed by | Vote    | For/Against Management |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1a.  | Election of Director: Lewis Hay, III                                                                                                                                   | Management  | For     | For                    |
| 1b.  | Election of Director: Julie A. Hill                                                                                                                                    | Management  | For     | For                    |
| 1c.  | Election of Director: Antonio F. Neri                                                                                                                                  | Management  | For     | For                    |
| 1d.  | Election of Director: Ramiro G. Peru                                                                                                                                   | Management  | For     | For                    |
| 2.   | To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2018.                                                          | Management  | For     | For                    |
| 3.   | Advisory vote to approve the compensation of our named executive officers.                                                                                             | Management  | For     | For                    |
| 4.   | To approve proposed amendments to our Articles of Incorporation to allow shareholders owning 20% or more of our common stock to call special meetings of shareholders. | Management  | For     | For                    |
| 5.   | Shareholder proposal to allow shareholders owning 10% or more of our common stock to call special meetings of shareholders.                                            | Shareholder | Against | For                    |

ARENA PHARMACEUTICALS, INC.

|               |             |              |             |
|---------------|-------------|--------------|-------------|
| Security      | 040047607   | Meeting Type | Annual      |
| Ticker Symbol | ARNA        | Meeting Date | 13-Jun-2018 |
| Record Date   | 24-Apr-2018 |              |             |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|----------|-------------|------|------------------------|
|------|----------|-------------|------|------------------------|

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|    |                                                                                                                                                                                                                                   |                      |            |         |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|------------|---------|
| 1. | DIRECTOR                                                                                                                                                                                                                          | Management           |            |         |
|    | 1                                                                                                                                                                                                                                 | Jayson Dallas, M.D.  | For        | For     |
|    | 2                                                                                                                                                                                                                                 | Oliver Fetzer, Ph.D. | For        | For     |
|    | 3                                                                                                                                                                                                                                 | Jennifer Jarrett     | For        | For     |
|    | 4                                                                                                                                                                                                                                 | Amit D. Munshi       | For        | For     |
|    | 5                                                                                                                                                                                                                                 | Garry A. Neil, M.D.  | For        | For     |
|    | 6                                                                                                                                                                                                                                 | Tina S. Nova, Ph.D.  | For        | For     |
|    | 7                                                                                                                                                                                                                                 | Randall E. Woods     | For        | For     |
| 2. | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.                                                                                 |                      | Management | For For |
| 3. | To approve the amendment and restatement of the Arena Pharmaceuticals, Inc., 2017 Long-Term Incentive Plan to, among other things, increase the number of shares authorized for issuance under the 2017 Long-Term Incentive Plan. |                      | Management | For For |
| 4. | To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2018.                                                                |                      | Management | For For |

ASCENDIS PHARMA A S

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 04351P101   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ASND        | <b>Meeting Date</b> | 29-May-2018 |
| <b>Record Date</b>   | 19-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                      | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | Election of Chairman of the Meeting                                                                                                                                                                                           | Management  | For  | For                    |
| 2.   | Report on the Company's Activities during the Past Year                                                                                                                                                                       | Management  | For  | For                    |
| 3.   | Presentation of Audited Annual Report with Auditor's Statement for Approval and Discharge of the Board of Directors and Management                                                                                            | Management  | For  | For                    |
| 4.   | Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report                                                                                                                                   | Management  | For  | For                    |
| 5a.  | Election of Board Member: Albert Cha (Class II)                                                                                                                                                                               | Management  | For  | For                    |
| 5b.  | Election of Board Member: Birgitte Volck (Class II)                                                                                                                                                                           | Management  | For  | For                    |
| 5c.  | Election of Board Member: Martin Olin (Class II)                                                                                                                                                                              | Management  | For  | For                    |
| 6.   | Election of State-authorized Public Auditor                                                                                                                                                                                   | Management  | For  | For                    |
| 7.   | Any proposals from the Board of Directors and/or Shareholders: The Board of Directors proposes to renew the authorisation to the Board of Directors to issue warrants. Please refer to the Notice for additional information. | Management  | For  | For                    |

**AURIS MEDICAL HOLDING AG**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | H03579101   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | EARS        | <b>Meeting Date</b> | 12-Mar-2018 |
| <b>Record Date</b>   | 09-Feb-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Proposed by | Vote | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | Approval of the merger between Auris Medical Holding AG (as transferring entity) and Auris Medical NewCo Holding AG (as surviving entity) according to the terms and conditions set forth by the merger agreement dated 9 February 2018 and based on the interim balance sheet of Auris Medical Holding AG as of 30 September 2017. German Version: Genehmigung der Fusion zwischen der Auris Medical Holding AG (als ubertragende Gesellschaft) und der Auris ... (due to space limits, see proxy statement for full proposal). | Management  | For  | For                    |
| 2.   | Discharge of liability for the members of the Board of Directors and the Persons entrusted with the Company's Management. German Version: Entlastung der Mitglieder des Verwaltungsrats und der mit der Geschäftsführung der Gesellschaft betrauten Personen.                                                                                                                                                                                                                                                                    | Management  | For  | For                    |
| 3.1  | Approval of the Compensation of the Board of Directors. German Version: Genehmigung der Vergütung des Verwaltungsrats.                                                                                                                                                                                                                                                                                                                                                                                                           | Management  | For  | For                    |
| 3.2  | Approval of the Compensation of the members of the Executive Management Committee for the 2019 financial year. German Version: Genehmigung der Vergütung der Geschäftsleitung für das Geschäftsjahr 2019.                                                                                                                                                                                                                                                                                                                        | Management  | For  | For                    |
| 4.1  | Re-election of Thomas Meyer as member and as Chairman of the Board of Directors. German Version: Wiederwahl von Thomas Meyer als Mitglied und als Präsident des Verwaltungsrats.                                                                                                                                                                                                                                                                                                                                                 | Management  | For  | For                    |
| 4.2  | Re-election of Armando Anido as member of the Board of Directors. German Version: Wiederwahl von Armando Anido als Mitglied des Verwaltungsrats.                                                                                                                                                                                                                                                                                                                                                                                 | Management  | For  | For                    |
| 4.3  | Re-election of Mats Peter Blom as member of the Board of Directors. German Version: Wiederwahl von Mats Peter Blom als Mitglied des Verwaltungsrats.                                                                                                                                                                                                                                                                                                                                                                             | Management  | For  | For                    |
| 4.4  | Re-election of Calvin W. Roberts as member of the Board of Directors. German Version: Wiederwahl von Calvin W. Roberts als Mitglied des Verwaltungsrats.                                                                                                                                                                                                                                                                                                                                                                         | Management  | For  | For                    |
| 4.5  | Election of Alain Munoz as member of the Board of Directors. German Version: Wahl von Alain Munoz als Mitglied des Verwaltungsrats.                                                                                                                                                                                                                                                                                                                                                                                              | Management  | For  | For                    |
| 5.1  | Re-election of Armando Anido as member of the Compensation Committee. German Version: Wiederwahl von Armando Anido als Mitglied des Vergütungsausschusses.                                                                                                                                                                                                                                                                                                                                                                       | Management  | For  | For                    |
| 5.2  | Election of Alain Munoz as member of the Compensation Committee. German Version: Wahl von Alain Munoz als Mitglied des Vergütungsausschusses.                                                                                                                                                                                                                                                                                                                                                                                    | Management  | For  | For                    |
| 6.   | Re-election of Deloitte AG as Auditors. German Version: Wiederwahl von Deloitte AG als Revisionsstelle.                                                                                                                                                                                                                                                                                                                                                                                                                          | Management  | For  | For                    |



## Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|    |                                                                                                                                                                  |            |     |     |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| 7. | Re-election of the Independent Proxy. German Version: Wiederwahl des unabhängigen Stimmrechtsvertreters.                                                         | Management | For | For |
| 8. | General instruction on new proposals of the Board of Directors. German Version: Allgemeine Weisungen zu nicht angekündigten Anträgen / Verhandlungsgegenständen. | Management | For | For |

---

**BEIGENE LTD**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 07725L102   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | BGNE        | <b>Meeting Date</b> | 06-Jun-2018 |
| <b>Record Date</b>   | 20-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                                                                     | Proposed by | Vote   | For/Against Management |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------|------------------------|
| 1.   | THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general ... (due to space limits, see proxy material for full proposal).                                                                              | Management  | For    | For                    |
| 2.   | THAT Michael Goller be and is hereby re-elected to serve as a ... (due to space limits, see proxy material for full proposal).                                                                                                                                               | Management  | For    | For                    |
| 3.   | THAT Thomas Malley be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management  | For    | For                    |
| 4.   | THAT the BeiGene, Ltd. 2018 Employee Share Purchase Plan be and is hereby approved and adopted.                                                                                                                                                                              | Management  | For    | For                    |
| 5.   | THAT the appointment of Ernst & Young Hua Ming LLP as the Company's independent registered public accounting firm for the ... (due to space limits, see proxy material for full proposal).                                                                                   | Management  | For    | For                    |
| 6.   | THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement for the Meeting, be and is hereby approved.                                                                                          | Management  | For    | For                    |
| 7.   | THAT, on a non-binding, advisory basis, future advisory votes on the compensation of the Company's named executive officers will be held at the frequency hereby approved.                                                                                                   | Management  | 1 Year | For                    |

**BIOCLIN THERAPEUTICS, INC.**

|                      |     |                     |                 |
|----------------------|-----|---------------------|-----------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Written Consent |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 27-Sep-2017     |
| <b>Record Date</b>   | N/A |                     |                 |

| Item | Proposal                       | Proposed by | Vote | For/Against Management |
|------|--------------------------------|-------------|------|------------------------|
| 1.   | Election of Director           | Management  | For  | For                    |
| 2.   | General Authorizing Resolution | Management  | For  | For                    |

**BIOCLIN THERAPEUTICS, INC.**

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|                      |     |                     |                 |
|----------------------|-----|---------------------|-----------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Written Consent |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 24-Apr-2018     |
| <b>Record Date</b>   | N/A |                     |                 |

| Item | Proposal                                                           | Proposed<br>by | Vote | For/Against<br>Management |
|------|--------------------------------------------------------------------|----------------|------|---------------------------|
| 1.   | Amendment and Restatement of Restated Certificate of Incorporation | Management     | For  | For                       |
| 2.   | Series B Preferred Stock Financing                                 | Management     | For  | For                       |
| 3.   | Waiver of Preemptive Rights                                        | Management     | For  | For                       |
| 4.   | Notice of Interested Party Transactions                            | Management     | For  | For                       |
| 5.   | Amendment of 2013 Stock and Option Grant Plan                      | Management     | For  | For                       |
| 6.   | General Authorizing Resolution                                     | Management     | For  | For                       |

---

**BIOCLIN THERAPEUTICS, INC.**

|                      |     |                     |                 |
|----------------------|-----|---------------------|-----------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Written Consent |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 21-May-2018     |
| <b>Record Date</b>   | N/A |                     |                 |

| Item | Proposal                       | Proposed by | Vote | For/Against Management |
|------|--------------------------------|-------------|------|------------------------|
| 1.   | Election of Director           | Management  | For  | For                    |
| 2.   | General Authorizing Resolution | Management  | For  | For                    |

**BIOGEN INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 09062X103   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | BIIB        | <b>Meeting Date</b> | 12-Jun-2018 |
| <b>Record Date</b>   | 17-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                              | Proposed by | Vote    | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1a.  | Election of Director: Alexander J. Denner                                                                                                                                             | Management  | For     | For                    |
| 1b.  | Election of Director: Caroline D. Dorsa                                                                                                                                               | Management  | For     | For                    |
| 1c.  | Election of Director: Nancy L. Leaming                                                                                                                                                | Management  | For     | For                    |
| 1d.  | Election of Director: Richard C. Mulligan                                                                                                                                             | Management  | For     | For                    |
| 1e.  | Election of Director: Robert W. Pangia                                                                                                                                                | Management  | For     | For                    |
| 1f.  | Election of Director: Stelios Papadopoulos                                                                                                                                            | Management  | For     | For                    |
| 1g.  | Election of Director: Brian S. Posner                                                                                                                                                 | Management  | For     | For                    |
| 1h.  | Election of Director: Eric K. Rowinsky                                                                                                                                                | Management  | For     | For                    |
| 1i.  | Election of Director: Lynn Schenk                                                                                                                                                     | Management  | For     | For                    |
| 1j.  | Election of Director: Stephen A. Sherwin                                                                                                                                              | Management  | For     | For                    |
| 1k.  | Election of Director: Michel Vounatsos                                                                                                                                                | Management  | For     | For                    |
| 2.   | To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2018.                    | Management  | For     | For                    |
| 3.   | Say on Pay - To approve an advisory vote on executive compensation.                                                                                                                   | Management  | For     | For                    |
| 4.   | Stockholder proposal requesting certain proxy access bylaw amendments.                                                                                                                | Shareholder | Against | For                    |
| 5.   | Stockholder proposal requesting a report on the extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements. | Shareholder | Against | For                    |

**BIOHAVEN PHARMACEUTICAL HLDG CO LTD**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | G11196105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | BHVN        | <b>Meeting Date</b> | 01-May-2018 |
| <b>Record Date</b>   | 26-Mar-2018 |                     |             |

| Item | Proposal                                                                                                | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1A.  | Election of Director: Dr. Eric I. Aguiar                                                                | Management  | For  | For                    |
| 1B.  | Election of Director: Dr. Albert Cha                                                                    | Management  | For  | For                    |
| 1C.  | Election of Director: Ms. Julia P. Gregory                                                              | Management  | For  | For                    |
| 2.   | Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal year 2018. | Management  | For  | For                    |

**BIOMARIN PHARMACEUTICAL INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 09061G101   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | BMRN        | <b>Meeting Date</b> | 05-Jun-2018 |
| <b>Record Date</b>   | 09-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                            | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                            | Management  |      |                        |
|      | 1 Jean-Jacques Bienaime                                                                                                                             |             | For  | For                    |
|      | 2 Willard Dere                                                                                                                                      |             | For  | For                    |
|      | 3 Michael Grey                                                                                                                                      |             | For  | For                    |
|      | 4 Elaine J. Heron                                                                                                                                   |             | For  | For                    |
|      | 5 Robert J. Hombach                                                                                                                                 |             | For  | For                    |
|      | 6 V. Bryan Lawlis                                                                                                                                   |             | For  | For                    |
|      | 7 Alan J. Lewis                                                                                                                                     |             | For  | For                    |
|      | 8 Richard A. Meier                                                                                                                                  |             | For  | For                    |
|      | 9 David E.I. Pyott                                                                                                                                  |             | For  | For                    |
|      | 10 Dennis J. Slamon                                                                                                                                 |             | For  | For                    |
| 2.   | To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2018. | Management  | For  | For                    |
| 3.   | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.                   | Management  | For  | For                    |

**BLUEBIRD BIO, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 09609G100   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | BLUE        | <b>Meeting Date</b> | 20-Jun-2018 |
| <b>Record Date</b>   | 23-Apr-2018 |                     |             |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                                                                                                                                    | Proposed<br>by | Vote | For/Against<br>Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------|---------------------------|
| 1a.  | Election of Class II Director: John O. Agwunobi, M.D.                                                                                                       | Management     | For  | For                       |
| 1b.  | Election of Class II Director: Mary Lynne Hedley, Ph.D                                                                                                      | Management     | For  | For                       |
| 1c.  | Election of Class II Director: Daniel S. Lynch                                                                                                              | Management     | For  | For                       |
| 2.   | To hold a non-binding advisory vote on the compensation paid to the Company's named executive officers.                                                     | Management     | For  | For                       |
| 3.   | To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management     | For  | For                       |

---

## BLUEPRINT MEDICINES CORPORATION

|               |             |              |             |
|---------------|-------------|--------------|-------------|
| Security      | 09627Y109   | Meeting Type | Annual      |
| Ticker Symbol | BPMC        | Meeting Date | 20-Jun-2018 |
| Record Date   | 23-Apr-2018 |              |             |

| Item | Proposal                                                                                                                                           | Proposed by | Vote   | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------|------------------------|
| 1.   | DIRECTOR                                                                                                                                           | Management  |        |                        |
|      | 1 Daniel S. Lynch                                                                                                                                  |             | For    | For                    |
|      | 2 George D. Demetri, M.D.                                                                                                                          |             | For    | For                    |
|      | 3 Lynn Seely, M.D.                                                                                                                                 |             | For    | For                    |
| 2.   | To approve an advisory vote on named executive officer compensation.                                                                               | Management  | For    | For                    |
| 3.   | To hold an advisory vote on the frequency of future advisory votes on named executive officer compensation.                                        | Management  | 1 Year | For                    |
| 4.   | Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ended December 31, 2018. | Management  | For    | For                    |

## BRISTOL-MYERS SQUIBB COMPANY

|               |             |              |             |
|---------------|-------------|--------------|-------------|
| Security      | 110122108   | Meeting Type | Annual      |
| Ticker Symbol | BMJ         | Meeting Date | 01-May-2018 |
| Record Date   | 14-Mar-2018 |              |             |

| Item | Proposal                                                                                                                                                             | Proposed by | Vote    | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1A.  | Election of Director: P. J. Arduini                                                                                                                                  | Management  | For     | For                    |
| 1B.  | Election of Director: J. Baselga, M.D., Ph.D.                                                                                                                        | Management  | For     | For                    |
| 1C.  | Election of Director: R. J. Bertolini                                                                                                                                | Management  | For     | For                    |
| 1D.  | Election of Director: G. Caforio, M.D.                                                                                                                               | Management  | For     | For                    |
| 1E.  | Election of Director: M. W. Emmens                                                                                                                                   | Management  | For     | For                    |
| 1F.  | Election of Director: M. Grobstein                                                                                                                                   | Management  | For     | For                    |
| 1G.  | Election of Director: A. J. Lacy                                                                                                                                     | Management  | For     | For                    |
| 1H.  | Election of Director: D. C. Paliwal                                                                                                                                  | Management  | For     | For                    |
| 1I.  | Election of Director: T. R. Samuels                                                                                                                                  | Management  | For     | For                    |
| 1J.  | Election of Director: G. L. Storch                                                                                                                                   | Management  | For     | For                    |
| 1K.  | Election of Director: V. L. Sato, Ph.D.                                                                                                                              | Management  | For     | For                    |
| 1L.  | Election of Director: K. H. Vousden, Ph.D.                                                                                                                           | Management  | For     | For                    |
| 2.   | Advisory vote to approve the compensation of our Named Executive Officers                                                                                            | Management  | For     | For                    |
| 3.   | Ratification of the appointment of an independent registered public accounting firm                                                                                  | Management  | For     | For                    |
| 4.   | Shareholder Proposal on Annual Report Disclosing How Risks Related to Public Concern Over Drug Pricing Strategies are Incorporated into Incentive Compensation Plans | Shareholder | Against | For                    |
| 5.   | Shareholder Proposal to Lower the Share Ownership Threshold to Call Special Shareholder Meetings                                                                     | Shareholder | Against | For                    |





**CARDINAL HEALTH, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 14149Y108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | CAH         | <b>Meeting Date</b> | 08-Nov-2017 |
| <b>Record Date</b>   | 11-Sep-2017 |                     |             |

| Item | Proposal                                                                                                                                                                                                                               | Proposed by | Vote    | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1A.  | ELECTION OF DIRECTOR: DAVID J. ANDERSON                                                                                                                                                                                                | Management  | For     | For                    |
| 1B.  | ELECTION OF DIRECTOR: COLLEEN F. ARNOLD                                                                                                                                                                                                | Management  | For     | For                    |
| 1C.  | ELECTION OF DIRECTOR: GEORGE S. BARRETT                                                                                                                                                                                                | Management  | For     | For                    |
| 1D.  | ELECTION OF DIRECTOR: CARRIE S. COX                                                                                                                                                                                                    | Management  | For     | For                    |
| 1E.  | ELECTION OF DIRECTOR: CALVIN DARDEN                                                                                                                                                                                                    | Management  | For     | For                    |
| 1F.  | ELECTION OF DIRECTOR: BRUCE L. DOWNEY                                                                                                                                                                                                  | Management  | For     | For                    |
| 1G.  | ELECTION OF DIRECTOR: PATRICIA A. HEMINGWAY HALL                                                                                                                                                                                       | Management  | For     | For                    |
| 1H.  | ELECTION OF DIRECTOR: CLAYTON M. JONES                                                                                                                                                                                                 | Management  | For     | For                    |
| 1I.  | ELECTION OF DIRECTOR: GREGORY B. KENNY                                                                                                                                                                                                 | Management  | For     | For                    |
| 1J.  | ELECTION OF DIRECTOR: NANCY KILLEFER                                                                                                                                                                                                   | Management  | For     | For                    |
| 1K.  | ELECTION OF DIRECTOR: DAVID P. KING                                                                                                                                                                                                    | Management  | For     | For                    |
| 2.   | PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT AUDITOR FOR THE FISCAL YEAR ENDING JUNE 30, 2018.                                                                                                           | Management  | For     | For                    |
| 3.   | PROPOSAL TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.                                                                                                                                | Management  | For     | For                    |
| 4.   | PROPOSAL TO VOTE, ON A NON-BINDING ADVISORY BASIS, ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE EXECUTIVE COMPENSATION.                                                                                                        | Management  | 1 Year  | For                    |
| 5.   | SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED, TO URGE THE BOARD OF DIRECTORS TO ADOPT A POLICY THAT THE CHAIRMAN OF THE BOARD BE AN INDEPENDENT DIRECTOR.                                                                               | Shareholder | Against | For                    |
| 6.   | SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED, TO REQUEST THAT THE BOARD OF DIRECTORS ADOPT A BYLAW PROVISION RESTRICTING MANAGEMENT'S ACCESS TO VOTE TALLIES PRIOR TO THE ANNUAL MEETING WITH RESPECT TO CERTAIN EXECUTIVE PAY MATTERS. | Shareholder | Against | For                    |

## CELGENE CORPORATION

|               |             |              |             |
|---------------|-------------|--------------|-------------|
| Security      | 151020104   | Meeting Type | Annual      |
| Ticker Symbol | CELG        | Meeting Date | 13-Jun-2018 |
| Record Date   | 19-Apr-2018 |              |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                                     | Proposed by | Vote    | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                                                                                                                                                                     | Management  |         |                        |
|      | 1 Mark J. Alles                                                                                                                                                                                                                                                                                                                              |             | For     | For                    |
|      | 2 R W Barker, D.Phil, OBE                                                                                                                                                                                                                                                                                                                    |             | For     | For                    |
|      | 3 Hans E. Bishop                                                                                                                                                                                                                                                                                                                             |             | For     | For                    |
|      | 4 Michael W. Bonney                                                                                                                                                                                                                                                                                                                          |             | For     | For                    |
|      | 5 Michael D. Casey                                                                                                                                                                                                                                                                                                                           |             | For     | For                    |
|      | 6 Carrie S. Cox                                                                                                                                                                                                                                                                                                                              |             | For     | For                    |
|      | 7 Michael A. Friedman, MD                                                                                                                                                                                                                                                                                                                    |             | For     | For                    |
|      | 8 Julia A. Haller, M.D.                                                                                                                                                                                                                                                                                                                      |             | For     | For                    |
|      | 9 P. A. Hemingway Hall                                                                                                                                                                                                                                                                                                                       |             | For     | For                    |
|      | 10 James J. Loughlin                                                                                                                                                                                                                                                                                                                         |             | For     | For                    |
|      | 11 Ernest Mario, Ph.D.                                                                                                                                                                                                                                                                                                                       |             | For     | For                    |
|      | 12 John H. Weiland                                                                                                                                                                                                                                                                                                                           |             | For     | For                    |
| 2.   | Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.                                                                                                                                                                                     | Management  | For     | For                    |
| 3.   | Approval, by non-binding vote, of executive compensation of the Company's named executive officers.                                                                                                                                                                                                                                          | Management  | For     | For                    |
| 4.   | Advisory vote on stockholder proposal to request the Company's Board of Directors to amend the Company's proxy access by-law provision to eliminate the limit on the number of stockholders that can aggregate their shares to achieve the holding requirement for nomination of directors, described in more detail in the proxy statement. | Shareholder | Against | For                    |
| 5.   | Advisory vote on stockholder proposal to request the Company's Board of Directors to adopt a policy and amend the Company's governing documents to require that the Chairman of the Board be an independent member, described in more detail in the proxy statement.                                                                         | Shareholder | For     | Against                |

## CENTENE CORPORATION

|               |             |              |             |
|---------------|-------------|--------------|-------------|
| Security      | 15135B101   | Meeting Type | Annual      |
| Ticker Symbol | CNC         | Meeting Date | 24-Apr-2018 |
| Record Date   | 23-Feb-2018 |              |             |

| Item | Proposal                                    | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------|-------------|------|------------------------|
| 1A.  | Election of Director: Jessica L. Blume      | Management  | For  | For                    |
| 1B.  | Election of Director: Frederick H. Eppinger | Management  | For  | For                    |
| 1C.  | Election of Director: David L. Steward      | Management  | For  | For                    |
| 2.   |                                             | Management  | For  | For                    |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

ADVISORY RESOLUTION TO APPROVE  
EXECUTIVE COMPENSATION.

|    |                                                                                                                                                     |            |     |     |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| 3. | RATIFICATION OF APPOINTMENT OF KPMG LLP<br>AS OUR INDEPENDENT REGISTERED PUBLIC<br>ACCOUNTING FIRM FOR THE FISCAL YEAR<br>ENDING DECEMBER 31, 2018. | Management | For | For |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|

---

**CLOVIS ONCOLOGY, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 189464100   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | CLVS        | <b>Meeting Date</b> | 07-Jun-2018 |
| <b>Record Date</b>   | 09-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                               | Proposed by | Vote   | For/Against Management |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                               | Management  |        |                        |
|      | 1 Patrick J. Mahaffy                                                                                                                                                   |             | For    | For                    |
|      | 2 M. James Barrett, Ph.D.                                                                                                                                              |             | For    | For                    |
|      | 3 Thorlef Spickschen                                                                                                                                                   |             | For    | For                    |
| 2.   | Approval and ratification of our Non-Employee Director Compensation Policy.                                                                                            | Management  | For    | For                    |
| 3.   | Approval of an advisory proposal on compensation of the Company's named executive officers, as disclosed in the attached proxy statement.                              | Management  | For    | For                    |
| 4.   | Approval of an advisory proposal on the preferred frequency of the stockholder vote on the compensation of the Company's named executive officers.                     | Management  | 1 Year | For                    |
| 5.   | Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018. | Management  | For    | For                    |

**COHERUS BIOSCIENCES INC**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 19249H103   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | CHRS        | <b>Meeting Date</b> | 23-May-2018 |
| <b>Record Date</b>   | 02-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                          | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                          | Management  |      |                        |
|      | 1 Christos Richards                                                                                                                               |             | For  | For                    |
|      | 2 V. Bryan Lawlis, Ph.D.                                                                                                                          |             | For  | For                    |
| 2.   | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**CRISPR THERAPEUTICS AG**

|                                                   |                                  |                                      |                       |
|---------------------------------------------------|----------------------------------|--------------------------------------|-----------------------|
| <b>Security<br/>Ticker Symbol<br/>Record Date</b> | H17182108<br>CRSP<br>02-Apr-2018 | <b>Meeting Type<br/>Meeting Date</b> | Annual<br>30-May-2018 |
|---------------------------------------------------|----------------------------------|--------------------------------------|-----------------------|

| Item | Proposal                                                                                                                                                                                  | Proposed<br>by | Vote | For/Against<br>Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------|---------------------------|
| 1.   | The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2017.                      | Management     | For  | For                       |
| 2.   | The approval of the appropriation of financial results.                                                                                                                                   | Management     | For  | For                       |
| 3.   | The discharge of the members of the Board of Directors and Executive Committee.                                                                                                           | Management     | For  | For                       |
| 4a.  | Re-election of the member to the Board of Director: Rodger Novak, M.D. (as member and Chairman)                                                                                           | Management     | For  | For                       |
| 4b.  | Election of the member to the Board of Director: Samarth Kulkarni, Ph.D.                                                                                                                  | Management     | For  | For                       |
| 4c.  | Re-election of the member to the Board of Director: Bradley Bolzon, Ph.D.                                                                                                                 | Management     | For  | For                       |
| 4d.  | Re-election of the member to the Board of Director: Ali Behbahani, M.D.                                                                                                                   | Management     | For  | For                       |
| 4e.  | Re-election of the member to the Board of Director: Pablo Cagnoni, M.D.                                                                                                                   | Management     | For  | For                       |
| 4f.  | Re-election of the member to the Board of Director: Kurt von Emster                                                                                                                       | Management     | For  | For                       |
| 4g.  | Re-election of the member to the Board of Director: Simeon J. George, M.D.                                                                                                                | Management     | For  | For                       |
| 4h.  | Re-election of the member to the Board of Director: Thomas Woiwode, Ph.D.                                                                                                                 | Management     | For  | For                       |
| 5a.  | Re-election of the member of the Compensation Committee: Thomas Woiwode, Ph.D.                                                                                                            | Management     | For  | For                       |
| 5b.  | Re-election of the member of the Compensation Committee: Pablo Cagnoni, M.D.                                                                                                              | Management     | For  | For                       |
| 5c.  | Re-election of the member of the Compensation Committee: Simeon J. George, M.D.                                                                                                           | Management     | For  | For                       |
| 6a.  | Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders. | Management     | For  | For                       |
| 6b.  | Binding vote on equity for members of the Board of Directors from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.                                     | Management     | For  | For                       |
| 6c.  | Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2018 to June 30, 2019.                                                     | Management     | For  | For                       |
| 6d.  | Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2018.                                                         | Management     | For  | For                       |
| 6e.  | Binding vote on equity for members of the Executive Committee from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.                                    | Management     | For  | For                       |
| 7.   | The approval of an increase in the Conditional Share Capital for Employee Benefit Plans.                                                                                                  | Management     | For  | For                       |
| 8.   |                                                                                                                                                                                           | Management     | For  | For                       |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|     |                                                                                                                                                                         |            |     |     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
|     | The approval of the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.                                                                                        |            |     |     |
| 9.  | The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase authorized share capital. | Management | For | For |
| 10. | The re-election of the independent voting rights representative.                                                                                                        | Management | For | For |
| 11. | The re-election of the auditors.                                                                                                                                        | Management | For | For |

**CYTOKINETICS, INCORPORATED**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 23282W605   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | CYTK        | <b>Meeting Date</b> | 16-May-2018 |
| <b>Record Date</b>   | 03-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                        | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                        | Management  |      |                        |
|      | 1 Robert I. Blum                                                                                                                                                                |             | For  | For                    |
|      | 2 Robert M. Califf M.D.                                                                                                                                                         |             | For  | For                    |
|      | 3 Sandford D. Smith                                                                                                                                                             |             | For  | For                    |
| 2.   | Ratification of selection of Ernst & Young LLP as the independent registered public accounting firm of Cytokinetics, Incorporated for the fiscal year ending December 31, 2018. | Management  | For  | For                    |
| 3.   | Approval, on an advisory basis, of the compensation of the named executive officers.                                                                                            | Management  | For  | For                    |

**CYTOMX THERAPEUTICS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 23284F105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | CTMX        | <b>Meeting Date</b> | 13-Jun-2018 |
| <b>Record Date</b>   | 23-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                        | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Director: Charles S. Fuchs                                                                                                          | Management  | For  | For                    |
| 1b.  | Election of Director: Hoyoung Huh                                                                                                               | Management  | For  | For                    |
| 2.   | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018. | Management  | For  | For                    |

**DERMIRA, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 24983L104   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | DERM        | <b>Meeting Date</b> | 12-Jun-2018 |
| <b>Record Date</b>   | 16-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                              | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                              | Management  |      |                        |
|      | 1 Matthew K. Fust                                                                                                                     |             | For  | For                    |
|      | 2 William R. Ringo                                                                                                                    |             | For  | For                    |
|      | 3 Kathleen Sebelius                                                                                                                   |             | For  | For                    |
| 2.   | Vote, on a non-binding advisory basis, on the compensation paid by us to our named executive officers for the year ended December 31, | Management  | For  | For                    |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|    |                                                                                                                                                  |            |         |         |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------|---------|
|    | 2017.                                                                                                                                            |            |         |         |
| 3. | Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018. | Management | For     | For     |
| 4. | Such other business as may properly come before the meeting or any adjournment thereof.                                                          | Management | Abstain | Against |

---



## EDITAS MEDICINE INC

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 28106W103   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | EDIT        | <b>Meeting Date</b> | 15-Jun-2018 |
| <b>Record Date</b>   | 18-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                        | Proposed by         | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                        | Management          |      |                        |
|      | 1                                                                                                                                                               | Andrew Hirsch       | For  | For                    |
|      | 2                                                                                                                                                               | Boris Nikolic, M.D. | For  | For                    |
| 2.   | Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management          | For  | For                    |

## EIGER BIOPHARMACEUTICALS, INC

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 28249U105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | EIGR        | <b>Meeting Date</b> | 12-Jun-2018 |
| <b>Record Date</b>   | 23-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                | Proposed by           | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                | Management            |      |                        |
|      | 1                                                                                                                                                                                       | Thomas J. Dietz, Ph.D | For  | For                    |
|      | 2                                                                                                                                                                                       | Eldon Mayer           | For  | For                    |
| 2.   | To ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018. | Management            | For  | For                    |

## ELI LILLY AND COMPANY

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 532457108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | LLY         | <b>Meeting Date</b> | 07-May-2018 |
| <b>Record Date</b>   | 12-Mar-2018 |                     |             |

| Item | Proposal                                                                                           | Proposed by | Vote | For/Against Management |
|------|----------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Director: K. Baicker                                                                   | Management  | For  | For                    |
| 1b.  | Election of Director: J. E. Fyrwald                                                                | Management  | For  | For                    |
| 1c.  | Election of Director: J. Jackson                                                                   | Management  | For  | For                    |
| 1d.  | Election of Director: E. R. Marram                                                                 | Management  | For  | For                    |
| 1e.  | Election of Director: J. P. Tai                                                                    | Management  | For  | For                    |
| 2.   | Approval, by non-binding vote, of the compensation paid to the company's named executive officers. | Management  | For  | For                    |
| 3.   |                                                                                                    | Management  | For  | For                    |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|     |                                                                                                                                                                                 |             |         |     |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|-----|
|     | Ratification of Ernst & Young LLP as the principal independent auditor for 2018.                                                                                                |             |         |     |
| 4.  | Approve amendments to the Articles of Incorporation to eliminate the classified board structure.                                                                                | Management  | For     | For |
| 5.  | Approve amendments to the Articles of Incorporation to eliminate supermajority voting provisions.                                                                               | Management  | For     | For |
| 6.  | Approve the Amended and Restated 2002 Lilly Stock Plan.                                                                                                                         | Management  | For     | For |
| 7.  | Shareholder proposal seeking support for the descheduling of cannabis.                                                                                                          | Shareholder | Against | For |
| 8.  | Shareholder proposal requesting report regarding direct and indirect political contributions.                                                                                   | Shareholder | Against | For |
| 9.  | Shareholder proposal requesting report on policies and practices regarding contract animal laboratories.                                                                        | Shareholder | Against | For |
| 10. | Shareholder proposal requesting report on extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements. | Shareholder | Against | For |

---

## ENDO INTERNATIONAL PLC

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | G30401106   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ENDP        | <b>Meeting Date</b> | 07-Jun-2018 |
| <b>Record Date</b>   | 13-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Director: Roger H. Kimmel                                                                                                                                                                                                                                                                                   | Management  | For  | For                    |
| 1b.  | Election of Director: Paul V. Campanelli                                                                                                                                                                                                                                                                                | Management  | For  | For                    |
| 1c.  | Election of Director: Shane M. Cooke                                                                                                                                                                                                                                                                                    | Management  | For  | For                    |
| 1d.  | Election of Director: Nancy J. Hutson, Ph.D.                                                                                                                                                                                                                                                                            | Management  | For  | For                    |
| 1e.  | Election of Director: Michael Hyatt                                                                                                                                                                                                                                                                                     | Management  | For  | For                    |
| 1f.  | Election of Director: Sharad S. Mansukani, M.D.                                                                                                                                                                                                                                                                         | Management  | For  | For                    |
| 1g.  | Election of Director: William P. Montague                                                                                                                                                                                                                                                                               | Management  | For  | For                    |
| 1h.  | Election of Director: Todd B. Sisitsky                                                                                                                                                                                                                                                                                  | Management  | For  | For                    |
| 2.   | To approve the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2018 and to authorize the Board of Directors, acting through the Audit Committee, to determine the independent registered public accounting firm's remuneration. | Management  | For  | For                    |
| 3.   | To approve, by advisory vote, named executive officer compensation.                                                                                                                                                                                                                                                     | Management  | For  | For                    |
| 4.   | To approve the Endo International plc Amended and Restated 2015 Stock Incentive Plan.                                                                                                                                                                                                                                   | Management  | For  | For                    |
| 5.   | To renew the Board's existing authority to issue shares under Irish law.                                                                                                                                                                                                                                                | Management  | For  | For                    |
| 6.   | To renew the Board's existing authority to opt-out of statutory pre-emption rights under Irish law.                                                                                                                                                                                                                     | Management  | For  | For                    |

## EPIZYME, INC.

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 29428V104   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | EPZM        | <b>Meeting Date</b> | 18-May-2018 |
| <b>Record Date</b>   | 23-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                      | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                      | Management  |      |                        |
|      | 1 Kevin Conroy                                                                                                                                                |             | For  | For                    |
|      | 2 Carl Goldfischer, M.D.                                                                                                                                      |             | For  | For                    |
|      | 3 Beth Seidenberg, M.D.                                                                                                                                       |             | For  | For                    |
| 2.   | Ratification of the appointment of Ernst & Young LLP as Epizyme's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

## ESPERION THERAPEUTICS INC

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 29664W105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ESPR        | <b>Meeting Date</b> | 23-May-2018 |
| <b>Record Date</b>   | 26-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                         | Proposed by | Vote | For/Against Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Class II Director: Jeffrey Berkowitz, J.D.                                                                                           | Management  | For  | For                    |
| 1b.  | Election of Class II Director: Antonio M. Gotto Jr., M.D., D.Phil.                                                                               | Management  | For  | For                    |
| 1c.  | Election of Class II Director: Nicole Vitullo                                                                                                    | Management  | For  | For                    |
| 2.   | To approve the advisory resolution on the compensation of our named executive officers                                                           | Management  | For  | For                    |
| 3.   | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018 | Management  | For  | For                    |

EUTHYMICS BIOSCIENCE, INC.

|                      |     |                     |                 |
|----------------------|-----|---------------------|-----------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Written Consent |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 11-Jul-2017     |
| <b>Record Date</b>   | N/A |                     |                 |

| Item | Proposal         | Proposed by | Vote | For/Against Management |
|------|------------------|-------------|------|------------------------|
| 1.   | Bridge Financing | Management  | For  | For                    |

**EUTHYMICS BIOSCIENCE, INC.**

|                      |     |                     |                 |
|----------------------|-----|---------------------|-----------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Written Consent |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 27-Oct-2017     |
| <b>Record Date</b>   | N/A |                     |                 |

| Item | Proposal             | Proposed by | Vote | For/Against Management |
|------|----------------------|-------------|------|------------------------|
| 1.   | Sale and Dissolution | Management  | For  | For                    |
| 2.   | Dissolution          | Management  | For  | For                    |
| 3.   | General              | Management  | For  | For                    |

**EVOLENT HEALTH, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 30050B101   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | EVH         | <b>Meeting Date</b> | 13-Jun-2018 |
| <b>Record Date</b>   | 17-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                            | Proposed by | Vote   | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------|------------------------|
| 1a.  | Election of Class III Director: Bruce Felt                                                                                                                          | Management  | For    | For                    |
| 1b.  | Election of Class III Director: Kenneth Samet                                                                                                                       | Management  | For    | For                    |
| 1c.  | Election of Class III Director: Cheryl Scott                                                                                                                        | Management  | For    | For                    |
| 1d.  | Election of Class III Director: Frank Williams                                                                                                                      | Management  | For    | For                    |
| 2.   | Proposal to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For    | For                    |
| 3.   | Proposal to approve an amendment of the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.                                                              | Management  | For    | For                    |
| 4.   | Proposal to approve the compensation of our named executive officers for 2017 on an advisory basis.                                                                 | Management  | For    | For                    |
| 5.   | Proposal to approve the selection of the frequency of future advisory votes on executive compensation on an advisory basis.                                         | Management  | 1 Year | For                    |

**EXELIXIS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 30161Q104   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | EXEL        | <b>Meeting Date</b> | 23-May-2018 |
| <b>Record Date</b>   | 29-Mar-2018 |                     |             |

| Item | Proposal                                           | Proposed by | Vote | For/Against Management |
|------|----------------------------------------------------|-------------|------|------------------------|
| 1.1  | Election of Class I Director: Charles Cohen, Ph.D. | Management  | For  | For                    |
| 1.2  |                                                    | Management  | For  | For                    |

## Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Election of Class I Director: George Poste, DVM, Ph.D.,  
FRS

|     |                                                                                                                                                                                                       |            |     |     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| 1.3 | Election of Class I Director: Jack L. Wyszomierski                                                                                                                                                    | Management | For | For |
| 2.  | To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis independent registered public accounting firm for the fiscal year ending December 28, 2018. | Management | For | For |
| 3.  | To approve, on an advisory basis, the compensation of Exelixis named executive officers, as disclosed in the accompanying Proxy Statement.                                                            | Management | For | For |

### FIBROGEN, INC.

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 31572Q808   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | FGEN        | <b>Meeting Date</b> | 05-Jun-2018 |
| <b>Record Date</b>   | 09-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                       | Proposed<br>by | Vote | For/Against<br>Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------|---------------------------|
| 1a.  | Election of Class I Director: Thomas B. Neff                                                                                                                                                                   | Management     | For  | For                       |
| 1b.  | Election of Class I Director: Jeffrey W. Henderson                                                                                                                                                             | Management     | For  | For                       |
| 1c.  | Election of Class I Director: James A. Schoeneck                                                                                                                                                               | Management     | For  | For                       |
| 2.   | To approve, on an advisory basis, the compensation of FibroGen s named executive officers, as disclosed in the proxy statement.                                                                                | Management     | For  | For                       |
| 3.   | To ratify the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of FibroGen for the year ending December 31, 2018. | Management     | For  | For                       |

FOAMIX PHARMACEUTICALS LTD

|               |             |              |             |
|---------------|-------------|--------------|-------------|
| Security      | M46135105   | Meeting Type | Special     |
| Ticker Symbol | FOMX        | Meeting Date | 27-Nov-2017 |
| Record Date   | 25-Oct-2017 |              |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                                                             | Proposed by | Vote    | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1.   | (I) PAY MR. DOMZALSKI ANNUAL COMPENSATION OF \$440,000 FOR HIS SERVICES AS THE CHIEF EXECUTIVE OFFICER OF THE COMPANY, EFFECTIVE AS OF JULY 1, 2017, (II) APPROVE MR. DOMZALSKI S CASH BONUS FOR THE SIX MONTH PERIOD COMMENCING AS OF JULY 1, 2017 UP TO A MAXIMUM AMOUNT OF \$132,000, SUBJECT TO ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL). | Management  | For     | For                    |
| 1A.  | DO YOU HAVE A PERSONAL INTEREST IN THE APPROVAL OF THIS PROPOSAL #1? MARK FOR = YES OR AGAINST = NO.                                                                                                                                                                                                                                                                 | Management  | Against | N/A                    |
| 2.   | AWARD MR. DOMZALSKI 327,720 OPTIONS AND 81,930 RSUS UNDER THE COMPANY S 2015 ISRAELI SHARE INCENTIVE PLAN AND ITS 2015 U.S. ADDENDUM.                                                                                                                                                                                                                                | Management  | For     | For                    |
| 2A.  | DO YOU HAVE A PERSONAL INTEREST IN THE APPROVAL OF THIS PROPOSAL #2? MARK FOR = YES OR AGAINST = NO.                                                                                                                                                                                                                                                                 | Management  | Against | N/A                    |

**FOAMIX PHARMACEUTICALS LTD**

|                                                   |                                  |                                      |                       |
|---------------------------------------------------|----------------------------------|--------------------------------------|-----------------------|
| <b>Security<br/>Ticker Symbol<br/>Record Date</b> | M46135105<br>FOMX<br>10-Apr-2018 | <b>Meeting Type<br/>Meeting Date</b> | Annual<br>08-May-2018 |
|---------------------------------------------------|----------------------------------|--------------------------------------|-----------------------|

| Item | Proposal                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Proposed<br>by | Vote    | For/Against<br>Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|---------|---------------------------|
| 1    | Appoint Kesselman & Kesselman (a member firm of PricewaterhouseCoopers International Limited, or PwC) an independent registered public accounting firm, as the Company's independent public accountants for the fiscal year ending December 31, 2018, and authorize the Board (or the Audit Committee, if such authority is delegated to it by the Board) to fix the remuneration of such independent public accountants in accordance with the volume and nature of their services. | Management     | For     | For                       |
| 2    | Ratify the election of Mr. David Domzalski as a director of the Company.                                                                                                                                                                                                                                                                                                                                                                                                             | Management     | For     | For                       |
| 3    | Approve the annual equity incentive awards to the Company's non- executive directors, as set out under Proposal 3 in the Company's proxy statement.                                                                                                                                                                                                                                                                                                                                  | Management     | For     | For                       |
| 4a   | Approve the equity incentive grants to Mr. Domzalski for 2017, as set out under Proposal 4(a) in the Company's proxy statement.                                                                                                                                                                                                                                                                                                                                                      | Management     | For     | For                       |
| 4a1  | Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 4(a)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against                                                                                                                                                                                                                                                            | Management     | Against | N/A                       |
| 4b   | Approve the terms of Mr. Domzalski's cash bonus and equity compensation for 2018, as set out under Proposal 4(b) of the Company's proxy statement.                                                                                                                                                                                                                                                                                                                                   | Management     | For     | For                       |
| 4b1  | Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 4(b)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against                                                                                                                                                                                                                                                            | Management     | Against | N/A                       |
| 5a   | Approve the 2016 equity conversion bonus for Dr. Tamarkin in respect of 2016, as set out under Proposal 5(a) of the Company's proxy statement                                                                                                                                                                                                                                                                                                                                        | Management     | For     | For                       |
| 5a1  | Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 5(a)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against                                                                                                                                                                                                                                                            | Management     | Against | N/A                       |
| 5b   | Approve Dr. Tamarkin's cash bonus in respect of the first half of 2017, as set out under Proposal 5(b) of the Company's proxy statement.                                                                                                                                                                                                                                                                                                                                             | Management     | For     | For                       |
| 5b1  | Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 5(b)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against                                                                                                                                                                                                                                                            | Management     | Against | N/A                       |
| 6.   | Approve the Company's Amended Compensation Policy, as set out under Proposal 6 of the Company's proxy statement.                                                                                                                                                                                                                                                                                                                                                                     | Management     | For     | For                       |
| 6a   | Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 6? If you vote FOR=YES or not at all your vote may not count for the                                                                                                                                                                                                                                                                                                           | Management     | Against | N/A                       |



Corresponding Proposal For= Yes, No=Against

---

**FOUNDATION MEDICINE, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 350465100   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | FMI         | <b>Meeting Date</b> | 21-Jun-2018 |
| <b>Record Date</b>   | 23-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                 | Proposed by | Vote | For/Against Management |
|------|------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                 | Management  |      |                        |
|      | 1 Alexis Borisy                                                                                                                          |             | For  | For                    |
|      | 2 Troy Cox                                                                                                                               |             | For  | For                    |
|      | 3 Michael Dougherty                                                                                                                      |             | For  | For                    |
|      | 4 Sandra Horning, M.D.                                                                                                                   |             | For  | For                    |
|      | 5 Evan Jones                                                                                                                             |             | For  | For                    |
|      | 6 Daniel O Day                                                                                                                           |             | For  | For                    |
|      | 7 Michael Pellini, M.D.                                                                                                                  |             | For  | For                    |
|      | 8 Michael Varney, Ph.D.                                                                                                                  |             | For  | For                    |
|      | 9 Krishna Yeshwant, M.D.                                                                                                                 |             | For  | For                    |
| 2.   | To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**GALAPAGOS N V**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 36315X101   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | GLPG        | <b>Meeting Date</b> | 24-Apr-2018 |
| <b>Record Date</b>   | 20-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                        | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 2.   | Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2017 and approval of the allocation of the annual result as proposed by the board of directors. | Management  | For  | N/A                    |
| 5.   | Acknowledgement and approval of the remuneration report.                                                                                                                                                                        | Management  | For  | N/A                    |
| 6.   | Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 December 2017.                                                 | Management  | For  | N/A                    |
| 7.1  | Re-appointment of Dr. Werner Cautreels as director of the Company.                                                                                                                                                              | Management  | For  | N/A                    |
| 7.2  | Re-appointment of Mr. Howard Rowe as director of the Company.                                                                                                                                                                   | Management  | For  | N/A                    |
| 8.   | Remuneration of directors.                                                                                                                                                                                                      | Management  | For  | N/A                    |
| 9.   | Offer of warrants.                                                                                                                                                                                                              | Management  | For  | N/A                    |

**GENOMEDX BIOSCIENCES, INC.**

|                      |     |                     |             |
|----------------------|-----|---------------------|-------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Special     |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 20-Nov-2017 |
| <b>Record Date</b>   | N/A |                     |             |

| Item | Proposal                                        | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------|-------------|------|------------------------|
| 1.   | Authorized Share Structure Amendment Resolution | Management  | For  | For                    |
| 2.   | Special Rights and Restrictions Resolution      | Management  | For  | For                    |
| 3.   | Class C Preferred Share Issuance Resolution     | Management  | For  | For                    |

**GENOMEDX BIOSCIENCES, INC.**

|                      |     |                     |            |
|----------------------|-----|---------------------|------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Special    |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 8-Jan-2018 |
| <b>Record Date</b>   | N/A |                     |            |

| Item | Proposal                                    | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------|-------------|------|------------------------|
| 1.   | Non-shareholders as Proxyholders Resolution | Management  | For  | For                    |
| 2.   | Special Rights and Restrictions Resolution  | Management  | For  | For                    |

**GENOMEDX BIOSCIENCES, INC.**

|                      |     |                     |            |
|----------------------|-----|---------------------|------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Special    |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 4-Feb-2018 |
| <b>Record Date</b>   | N/A |                     |            |

| Item | Proposal                                        | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------|-------------|------|------------------------|
| 1.   | Non-shareholders as Proxyholders Resolution     | Management  | For  | For                    |
| 2.   | Authorized Share Structure Amendment Resolution | Management  | For  | For                    |
| 3.   | Articles Amendment Resolution                   | Management  | For  | For                    |
| 4.   | New Preferred Share Issuance Resolution         | Management  | For  | For                    |

**GENOMEDX BIOSCIENCES, INC.**

|                      |     |                     |             |
|----------------------|-----|---------------------|-------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Special     |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 31-Mar-2018 |
| <b>Record Date</b>   | N/A |                     |             |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                        | Proposed<br>by | Vote | For/Against<br>Management |
|------|-------------------------------------------------|----------------|------|---------------------------|
| 1.   | Non-shareholders as Proxyholders Resolution     | Management     | For  | For                       |
| 2.   | Authorized Share Structure Amendment Resolution | Management     | For  | For                       |
| 3.   | Articles Amendment Resolution                   | Management     | For  | For                       |
| 4.   | New Preferred Share Issuance Resolution         | Management     | For  | For                       |

**GENOMEDX BIOSCIENCES, INC.**

|                      |     |                     |             |
|----------------------|-----|---------------------|-------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Special     |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 29-Jun-2018 |
| <b>Record Date</b>   | N/A |                     |             |

| Item | Proposal                                    | Proposed<br>by | Vote | For/Against<br>Management |
|------|---------------------------------------------|----------------|------|---------------------------|
| 1.   | Non-shareholders as Proxyholders Resolution | Management     | For  | For                       |
| 2.   | Domestication Resolution                    | Management     | For  | For                       |

---

**GILEAD SCIENCES, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 375558103   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | GILD        | <b>Meeting Date</b> | 09-May-2018 |
| <b>Record Date</b>   | 16-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                   | Proposed by | Vote    | For/Against Management |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1a.  | Election of Director: John F. Cogan, Ph.D.                                                                                                                                                                 | Management  | For     | For                    |
| 1b.  | Election of Director: Jacqueline K. Barton, Ph.D.                                                                                                                                                          | Management  | For     | For                    |
| 1c.  | Election of Director: Kelly A. Kramer                                                                                                                                                                      | Management  | For     | For                    |
| 1d.  | Election of Director: Kevin E. Lofton                                                                                                                                                                      | Management  | For     | For                    |
| 1e.  | Election of Director: John C. Martin, Ph.D.                                                                                                                                                                | Management  | For     | For                    |
| 1f.  | Election of Director: John F. Milligan, Ph.D.                                                                                                                                                              | Management  | For     | For                    |
| 1g.  | Election of Director: Richard J. Whitley, M.D.                                                                                                                                                             | Management  | For     | For                    |
| 1h.  | Election of Director: Gayle E. Wilson                                                                                                                                                                      | Management  | For     | For                    |
| 1i.  | Election of Director: Per Wold-Olsen                                                                                                                                                                       | Management  | For     | For                    |
| 2.   | To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2018. | Management  | For     | For                    |
| 3.   | To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.                                                                                    | Management  | For     | For                    |
| 4.   | To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairman of the Board of Directors be an independent director.                  | Shareholder | Against | For                    |
| 5.   | To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board take steps to permit stockholder action by written consent.                                             | Shareholder | Against | For                    |

**GLOBAL BLOOD THERAPEUTICS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 37890U108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | GBT         | <b>Meeting Date</b> | 20-Jun-2018 |
| <b>Record Date</b>   | 23-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                             | Proposed by | Vote   | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                             | Management  |        |                        |
|      | 1 Scott W. Morrison                                                                                                                                                  |             | For    | For                    |
|      | 2 Deval L. Patrick                                                                                                                                                   |             | For    | For                    |
|      | 3 Mark L. Perry                                                                                                                                                      |             | For    | For                    |
| 2.   | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.                       | Management  | For    | For                    |
| 3.   | Recommendation, on a non-binding, advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company's named executive officers. | Management  | 1 Year | For                    |

# Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|    |                                                                                                                                                               |            |     |     |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| 4. | Ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. | Management | For | For |
| 5. | Transaction of such other business as may properly come before the meeting or any adjournment or postponement thereof.                                        | Management | For | For |

**GW PHARMACEUTICALS PLC**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 36197T103   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | GWPH        | <b>Meeting Date</b> | 14-Mar-2018 |
| <b>Record Date</b>   | 05-Feb-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                            | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| O1   | TO RECEIVE, CONSIDER AND ADOPT THE DIRECTORS AND AUDITORS REPORTS AND STATEMENT OF ACCOUNTS FOR THE YEAR ENDED 30 SEPTEMBER 2017 AND NOTE THAT THE DIRECTORS DO NOT RECOMMEND PAYMENT OF A DIVIDEND | Management  | For  | N/A                    |
| O2   | TO APPROVE THE DIRECTORS REMUNERATION REPORT                                                                                                                                                        | Management  | For  | N/A                    |
| O3   | TO APPROVE THE DIRECTORS REMUNERATION POLICY                                                                                                                                                        | Management  | For  | N/A                    |
| O4   | TO RE-ELECT JUSTIN GOVER AS A DIRECTOR                                                                                                                                                              | Management  | For  | N/A                    |
| O5   | TO ELECT CATHERINE MACKEY AS A DIRECTOR                                                                                                                                                             | Management  | For  | N/A                    |
| O6   | TO ELECT ALICIA SECOR AS A DIRECTOR                                                                                                                                                                 | Management  | For  | N/A                    |
| O7   | TO ELECT WILLIAM WALDEGRAVE AS A DIRECTOR                                                                                                                                                           | Management  | For  | N/A                    |
| O8   | TO RE-APPOINT DELOITTE LLP AS AUDITOR                                                                                                                                                               | Management  | For  | N/A                    |
| O9   | To authorise the Directors to determine the Auditor s remuneration                                                                                                                                  | Management  | For  | N/A                    |
| O10  | To authorise the Directors to allot shares pursuant to Section 551 of the Companies Act 2006 (the 2006 Act )                                                                                        | Management  | For  | N/A                    |
| S11  | Subject to the passing of Resolution 10, to authorise the ...(due to space limits, see proxy material for full proposal).                                                                           | Management  | For  | N/A                    |
| S12  | To adopt new articles of association of the Company in ...(due to space limits, see proxy material for full proposal).                                                                              | Management  | For  | N/A                    |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**HENRY SCHEIN, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 806407102   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | HSIC        | <b>Meeting Date</b> | 31-May-2018 |
| <b>Record Date</b>   | 02-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                              | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Director: Barry J. Alperin                                                                                                                                                                                | Management  | For  | For                    |
| 1b.  | Election of Director: Gerald A. Benjamin                                                                                                                                                                              | Management  | For  | For                    |
| 1c.  | Election of Director: Stanley M. Bergman                                                                                                                                                                              | Management  | For  | For                    |
| 1d.  | Election of Director: James P. Breslawski                                                                                                                                                                             | Management  | For  | For                    |
| 1e.  | Election of Director: Paul Brons                                                                                                                                                                                      | Management  | For  | For                    |
| 1f.  | Election of Director: Shira Goodman                                                                                                                                                                                   | Management  | For  | For                    |
| 1g.  | Election of Director: Joseph L. Herring                                                                                                                                                                               | Management  | For  | For                    |
| 1h.  | Election of Director: Kurt P. Kuehn                                                                                                                                                                                   | Management  | For  | For                    |
| 1i.  | Election of Director: Philip A. Laskawy                                                                                                                                                                               | Management  | For  | For                    |
| 1j.  | Election of Director: Anne H. Margulies                                                                                                                                                                               | Management  | For  | For                    |
| 1k.  | Election of Director: Mark E. Mlotek                                                                                                                                                                                  | Management  | For  | For                    |
| 1l.  | Election of Director: Steven Paladino                                                                                                                                                                                 | Management  | For  | For                    |
| 1m.  | Election of Director: Carol Raphael                                                                                                                                                                                   | Management  | For  | For                    |
| 1n.  | Election of Director: E. Dianne Rekow, DDS, Ph.D.                                                                                                                                                                     | Management  | For  | For                    |
| 1o.  | Election of Director: Bradley T. Sheares, Ph.D.                                                                                                                                                                       | Management  | For  | For                    |
| 2.   | Proposal to amend the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 240,000,000 to 480,000,000.                           | Management  | For  | For                    |
| 3.   | Proposal to amend the Company's Amended and Restated Certificate of Incorporation, as amended, to add a forum selection clause.                                                                                       | Management  | For  | For                    |
| 4.   | Proposal to amend and restate the Company's Amended and Restated Certificate of Incorporation, as amended, to incorporate certain technical, administrative and updating changes as set forth in the Proxy Statement. | Management  | For  | For                    |
| 5.   | Proposal to approve, by non-binding vote, the 2017 compensation paid to the Company's Named Executive Officers.                                                                                                       | Management  | For  | For                    |
| 6.   | Proposal to ratify the selection of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 29, 2018.                                                         | Management  | For  | For                    |

**HUMANA INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 444859102   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | HUM         | <b>Meeting Date</b> | 19-Apr-2018 |
| <b>Record Date</b>   | 26-Feb-2018 |                     |             |

| Item | Proposal                                | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Director: Kurt J. Hilzinger | Management  | For  | For                    |



# Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|     |                                                                                                                                   |            |     |     |
|-----|-----------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| 1b. | Election of Director: Frank J. Bisignano                                                                                          | Management | For | For |
| 1c. | Election of Director: Bruce D. Broussard                                                                                          | Management | For | For |
| 1d. | Election of Director: Frank A. D. Amelio                                                                                          | Management | For | For |
| 1e. | Election of Director: Karen B. DeSalvo, M.D.                                                                                      | Management | For | For |
| 1f. | Election of Director: W. Roy Dunbar                                                                                               | Management | For | For |
| 1g. | Election of Director: David A. Jones, Jr.                                                                                         | Management | For | For |
| 1h. | Election of Director: William J. McDonald                                                                                         | Management | For | For |
| 1i. | Election of Director: William E. Mitchell                                                                                         | Management | For | For |
| 1j. | Election of Director: David B. Nash, M.D.                                                                                         | Management | For | For |
| 1k. | Election of Director: James J. O'Brien                                                                                            | Management | For | For |
| 1l. | Election of Director: Marissa T. Peterson                                                                                         | Management | For | For |
| 2.  | The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm. | Management | For | For |
| 3.  | The approval of the compensation of the named executive officers as disclosed in the 2018 proxy statement.                        | Management | For | For |

**IDEXX LABORATORIES, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 45168D104   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | IDXX        | <b>Meeting Date</b> | 09-May-2018 |
| <b>Record Date</b>   | 16-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                        | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Director: Bruce L. Claflin                                                                                                                                                                                          | Management  | For  | For                    |
| 1b.  | Election of Director: Daniel M. Junius                                                                                                                                                                                          | Management  | For  | For                    |
| 2.   | Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year. | Management  | For  | For                    |
| 3.   | Approval of the Adoption of the IDEXX Laboratories, Inc. 2018 Incentive Plan. To approve the Company's 2018 Stock Incentive Plan.                                                                                               | Management  | For  | For                    |
| 4.   | Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation.                                                                                                   | Management  | For  | For                    |

**ILLUMINA, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 452327109   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | ILMN        | <b>Meeting Date</b> | 23-May-2018 |
| <b>Record Date</b>   | 29-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                          | Proposed by | Vote    | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1a.  | Election of Director: Jay T. Flatley                                                                                                              | Management  | For     | For                    |
| 1b.  | Election of Director: John W. Thompson                                                                                                            | Management  | For     | For                    |
| 1c.  | Election of Director: Gary S. Guthart, Ph.D.                                                                                                      | Management  | For     | For                    |
| 2.   | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 30, 2018. | Management  | For     | For                    |
| 3.   | To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.                           | Management  | For     | For                    |
| 4.   | To approve, on an advisory basis, a stockholder proposal to elect each director annually.                                                         | Shareholder | Against | For                    |

**ILLUMINOSS MEDICAL, INC.**

|                      |     |                     |                 |
|----------------------|-----|---------------------|-----------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Written Consent |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 14-Nov-2017     |
| <b>Record Date</b>   | N/A |                     |                 |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                                | Proposed<br>by | Vote | For/Against<br>Management |
|------|---------------------------------------------------------|----------------|------|---------------------------|
| 1.   | Sixth Amended and Restated Certificate of Incorporation | Management     | For  | For                       |
| 2.   | Convertible Note Financing                              | Management     | For  | For                       |
| 3.   | Amendment of March 2017 Notes and Warrants              | Management     | For  | For                       |
| 4.   | Anti-Dilution                                           | Management     | For  | For                       |
| 5.   | General Resolutions                                     | Management     | For  | For                       |

---

**INCYTE CORPORATION**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 45337C102   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | INCY        | <b>Meeting Date</b> | 01-May-2018 |
| <b>Record Date</b>   | 05-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.1  | Election of Director: Julian C. Baker                                                                                   | Management  | For  | For                    |
| 1.2  | Election of Director: Jean-Jacques Bienaime                                                                             | Management  | For  | For                    |
| 1.3  | Election of Director: Paul A. Brooke                                                                                    | Management  | For  | For                    |
| 1.4  | Election of Director: Paul J. Clancy                                                                                    | Management  | For  | For                    |
| 1.5  | Election of Director: Wendy L. Dixon                                                                                    | Management  | For  | For                    |
| 1.6  | Election of Director: Jacquelyn A. Fouse                                                                                | Management  | For  | For                    |
| 1.7  | Election of Director: Paul A. Friedman                                                                                  | Management  | For  | For                    |
| 1.8  | Election of Director: Herve Hoppenot                                                                                    | Management  | For  | For                    |
| 2.   | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.               | Management  | For  | For                    |
| 3.   | To approve amendments to the Company's Amended and Restated 2010 Stock Incentive Plan.                                  | Management  | For  | For                    |
| 4.   | To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2018. | Management  | For  | For                    |

**INNOVIVA INC**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 45781M101   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | INVA        | <b>Meeting Date</b> | 24-Apr-2018 |
| <b>Record Date</b>   | 19-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                 | Proposed by | Vote | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Director: George W. Bickerstaff, III                                                                                                                                                         | Management  | For  | For                    |
| 1b.  | Election of Director: Mark DiPaolo, Esq.                                                                                                                                                                 | Management  | For  | For                    |
| 1c.  | Election of Director: Jules Haimovitz                                                                                                                                                                    | Management  | For  | For                    |
| 1d.  | Election of Director: Odysseas D. Kostas, M.D.                                                                                                                                                           | Management  | For  | For                    |
| 1e.  | Election of Director: Sarah Schlesinger, M.D.                                                                                                                                                            | Management  | For  | For                    |
| 2.   | Approve the non-binding advisory resolution regarding executive compensation.                                                                                                                            | Management  | For  | For                    |
| 3.   | Ratify the selection by the Audit Committee of the Board of Directors for Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**INTELLIA THERAPEUTICS, INC.**

|                 |           |                     |        |
|-----------------|-----------|---------------------|--------|
| <b>Security</b> | 45826J105 | <b>Meeting Type</b> | Annual |
|-----------------|-----------|---------------------|--------|

# Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Ticker Symbol</b> | NTLA        | <b>Meeting Date</b> | 17-May-2018 |
| <b>Record Date</b>   | 04-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                           | Proposed by | Vote | For/Against Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Class II Director: Frank Verwiel                                                                                                                       | Management  | For  | For                    |
| 2.   | Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

## IONIS PHARMACEUTICALS, INC.

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 462222100   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | IONS        | <b>Meeting Date</b> | 23-May-2018 |
| <b>Record Date</b>   | 26-Mar-2018 |                     |             |

| Item | Proposal                                                                                                      | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                      | Management  |      |                        |
|      | 1 Frederick T. Muto                                                                                           |             | For  | For                    |
|      | 2 Breaux B. Castleman                                                                                         |             | For  | For                    |
| 2.   | To approve, by non-binding vote, executive compensation.                                                      | Management  | For  | For                    |
| 3.   | Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2018 fiscal year. | Management  | For  | For                    |

**JAZZ PHARMACEUTICALS PLC**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | G50871105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | JAZZ        | <b>Meeting Date</b> | 02-Aug-2018 |
| <b>Record Date</b>   | 06-Jun-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                              | Proposed by | Vote   | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------|------------------------|
| 1a.  | Election of Director: Peter Gray                                                                                                                                                                                                                                                                                                      | Management  | For    | For                    |
| 1b.  | Election of Director: Kenneth W. O Keefe                                                                                                                                                                                                                                                                                              | Management  | For    | For                    |
| 1c.  | Election of Director: Elmar Schnee                                                                                                                                                                                                                                                                                                    | Management  | For    | For                    |
| 1d.  | Election of Director: Catherine A. Sohn                                                                                                                                                                                                                                                                                               | Management  | For    | For                    |
| 2.   | To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine the independent auditors remuneration. | Management  | For    | For                    |
| 3.   | To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc s named executive officers as disclosed in the proxy statement.                                                                                                                                                                             | Management  | For    | For                    |
| 4.   | To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc s named executive officers.                                                                                                                                                                | Management  | 1 Year | For                    |

**JOHNSON & JOHNSON**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 478160104   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | JNJ         | <b>Meeting Date</b> | 26-Apr-2018 |
| <b>Record Date</b>   | 27-Feb-2018 |                     |             |

| Item | Proposal                                                                                                                | Proposed by | Vote    | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1a.  | Election of Director: Mary C. Beckerle                                                                                  | Management  | For     | For                    |
| 1b.  | Election of Director: D. Scott Davis                                                                                    | Management  | For     | For                    |
| 1c.  | Election of Director: Ian E. L. Davis                                                                                   | Management  | For     | For                    |
| 1d.  | Election of Director: Jennifer A. Doudna                                                                                | Management  | For     | For                    |
| 1e.  | Election of Director: Alex Gorsky                                                                                       | Management  | For     | For                    |
| 1f.  | Election of Director: Mark B. McClellan                                                                                 | Management  | For     | For                    |
| 1g.  | Election of Director: Anne M. Mulcahy                                                                                   | Management  | For     | For                    |
| 1h.  | Election of Director: William D. Perez                                                                                  | Management  | For     | For                    |
| 1i.  | Election of Director: Charles Prince                                                                                    | Management  | For     | For                    |
| 1j.  | Election of Director: A. Eugene Washington                                                                              | Management  | For     | For                    |
| 1k.  | Election of Director: Ronald A. Williams                                                                                | Management  | For     | For                    |
| 2.   | Advisory Vote to Approve Named Executive Officer Compensation                                                           | Management  | For     | For                    |
| 3.   | Ratification of Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting Firm for 2018 | Management  | For     | For                    |
| 4.   |                                                                                                                         | Shareholder | Against | For                    |

# Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

Shareholder Proposal - Accounting for Litigation and  
Compliance in Executive Compensation Performance  
Measures

|    |                                                                                             |             |         |     |
|----|---------------------------------------------------------------------------------------------|-------------|---------|-----|
| 5. | Shareholder Proposal - Amendment to Shareholder Ability to Call Special Shareholder Meeting | Shareholder | Against | For |
|----|---------------------------------------------------------------------------------------------|-------------|---------|-----|

## LEXICON PHARMACEUTICALS, INC.

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 528872302   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | LXRX        | <b>Meeting Date</b> | 26-Apr-2018 |
| <b>Record Date</b>   | 26-Feb-2018 |                     |             |

| Item | Proposal                                                                                                                                          | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                          | Management  |      |                        |
|      | 1 Philippe J. Amouyal                                                                                                                             |             | For  | For                    |
|      | 2 Lonnel Coats                                                                                                                                    |             | For  | For                    |
|      | 3 Frank P. Palantoni                                                                                                                              |             | For  | For                    |
| 2.   | Advisory vote to approve the compensation paid to the Company's named executive officers.                                                         | Management  | For  | For                    |
| 3.   | Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**MERCK & CO., INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 58933Y105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | MRK         | <b>Meeting Date</b> | 22-May-2018 |
| <b>Record Date</b>   | 28-Mar-2018 |                     |             |

| Item | Proposal                                                                                                 | Proposed by | Vote    | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1a.  | Election of Director: Leslie A. Brun                                                                     | Management  | For     | For                    |
| 1b.  | Election of Director: Thomas R. Cech                                                                     | Management  | For     | For                    |
| 1c.  | Election of Director: Pamela J. Craig                                                                    | Management  | For     | For                    |
| 1d.  | Election of Director: Kenneth C. Frazier                                                                 | Management  | For     | For                    |
| 1e.  | Election of Director: Thomas H. Glocer                                                                   | Management  | For     | For                    |
| 1f.  | Election of Director: Rochelle B. Lazarus                                                                | Management  | For     | For                    |
| 1g.  | Election of Director: John H. Noseworthy                                                                 | Management  | For     | For                    |
| 1h.  | Election of Director: Paul B. Rothman                                                                    | Management  | For     | For                    |
| 1i.  | Election of Director: Patricia F. Russo                                                                  | Management  | For     | For                    |
| 1j.  | Election of Director: Craig B. Thompson                                                                  | Management  | For     | For                    |
| 1k.  | Election of Director: Inge G. Thulin                                                                     | Management  | For     | For                    |
| 1l.  | Election of Director: Wendell P. Weeks                                                                   | Management  | For     | For                    |
| 1m.  | Election of Director: Peter C. Wendell                                                                   | Management  | For     | For                    |
| 2.   | Non-binding advisory vote to approve the compensation of our named executive officers.                   | Management  | For     | For                    |
| 3.   | Ratification of the appointment of the Company's independent registered public accounting firm for 2018. | Management  | For     | For                    |
| 4.   | Shareholder proposal concerning shareholders' right to act by written consent.                           | Shareholder | Against | For                    |

**MILESTONE PHARMACEUTICALS, INC.**

|                      |     |                     |             |
|----------------------|-----|---------------------|-------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 27-Jun-2018 |
| <b>Record Date</b>   | N/A |                     |             |

| Item | Proposal                                                                                           | Proposed by | Vote | For/Against Management |
|------|----------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | Acceptance of the Audited Financial Statements of the Corporation for year ended December 31, 2017 | Management  | For  | For                    |
| 2.   | Election of Directors                                                                              | Management  | For  | For                    |
| 3.   | Appointment of Auditors                                                                            | Management  | For  | For                    |
| 4.   | Transaction of other Business                                                                      | Management  | For  | For                    |

**MOLECULAR TEMPLATES, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 608550109   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | MTEM        | <b>Meeting Date</b> | 31-May-2018 |
| <b>Record Date</b>   | 10-Apr-2018 |                     |             |



Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                                                                                                                    | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                    | Management  |      |                        |
|      | 1 Jonathan Lanfear                                                                                                                          |             | For  | For                    |
|      | 2 Scott Morenstein                                                                                                                          |             | For  | For                    |
| 2.   | Approve the 2018 Equity Incentive Plan.                                                                                                     | Management  | For  | For                    |
| 3.   | Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending 2018. | Management  | For  | For                    |
| 4.   | Approve by an advisory vote the compensation of our named executive officers, as disclosed in the accompanying proxy statement.             | Management  | For  | For                    |

## MYLAN N.V.

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | N59465109   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | MYL         | <b>Meeting Date</b> | 29-Jun-2018 |
| <b>Record Date</b>   | 01-Jun-2018 |                     |             |

| Item | Proposal                                                                                                                                   | Proposed by | Vote | For/Against Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1A.  | Appointment of Director: Heather Bresch                                                                                                    | Management  | For  | For                    |
| 1B.  | Appointment of Director: Hon. Robert J. Cindrich                                                                                           | Management  | For  | For                    |
| 1C.  | Appointment of Director: Robert J. Coury                                                                                                   | Management  | For  | For                    |
| 1D.  | Appointment of Director: JoEllen Lyons Dillon                                                                                              | Management  | For  | For                    |
| 1E.  | Appointment of Director: Neil Dimick, C.P.A.                                                                                               | Management  | For  | For                    |
| 1F.  | Appointment of Director: Melina Higgins                                                                                                    | Management  | For  | For                    |
| 1G.  | Appointment of Director: Harry A. Korman                                                                                                   | Management  | For  | For                    |
| 1H.  | Appointment of Director: Rajiv Malik                                                                                                       | Management  | For  | For                    |
| 1I.  | Appointment of Director: Mark W. Parrish                                                                                                   | Management  | For  | For                    |
| 1J.  | Appointment of Director: Pauline van der Meer Mohr                                                                                         | Management  | For  | For                    |
| 1K.  | Appointment of Director: Randall L. (Pete) Vanderveen, Ph.D.                                                                               | Management  | For  | For                    |
| 1L.  | Appointment of Director: Sjoerd S. Vollebregt                                                                                              | Management  | For  | For                    |
| 2.   | Approval, on an advisory basis, of the compensation of the named executive officers of the Company                                         | Management  | For  | For                    |
| 3.   | Adoption of the Dutch annual accounts for fiscal year 2017                                                                                 | Management  | For  | For                    |
| 4.   | Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2018 | Management  | For  | For                    |
| 5.   | Instruction to Deloitte Accountants B.V. for the audit of the Company's Dutch statutory annual accounts for fiscal year 2018               | Management  | For  | For                    |
| 6.   | Authorization of the Board to acquire shares in the capital of the Company                                                                 | Management  | For  | For                    |

## MYOVANT SCIENCES LTD.

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | G637AM102   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | MYOV        | <b>Meeting Date</b> | 18-Aug-2017 |
| <b>Record Date</b>   | 14-Jul-2017 |                     |             |

| Item | Proposal                                                                                                                                                  | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.1  | ELECTION OF CLASS I DIRECTOR: MARK ALTMAYER                                                                                                               | Management  | For  | For                    |
| 1.2  | ELECTION OF CLASS I DIRECTOR: TERRIE CURRAN                                                                                                               | Management  | For  | For                    |
| 1.3  | ELECTION OF CLASS I DIRECTOR: KEITH MANCHESTER, M.D.                                                                                                      | Management  | For  | For                    |
| 2.   | TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF ERNST & YOUNG LLP AS MYOVANT'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR MYOVANT'S | Management  | For  | For                    |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

FISCAL YEAR ENDING MARCH 31, 2018, TO  
APPOINT ERNST & YOUNG LLP AS AUDITOR FOR  
STATUTORY PURPOSES UNDER THE BERMUDA  
COMPANIES ACT 1981, AS AMENDED, FOR  
MYOVANT S ... (DUE TO SPACE LIMITS, SEE PROXY  
STATEMENT FOR FULL PROPOSAL).

---

**MYOVANT SCIENCES LTD.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | G637AM102   | <b>Meeting Type</b> | Special     |
| <b>Ticker Symbol</b> | MYOV        | <b>Meeting Date</b> | 09-Feb-2018 |
| <b>Record Date</b>   | 22-Jan-2018 |                     |             |

| Item | Proposal                                                                                             | Proposed by | Vote | For/Against Management |
|------|------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | To approve an amendment to our Bye-laws to declassify the Board of Directors.                        | Management  | For  | For                    |
| 2.   | To approve an amendment to our Bye-laws to modify shareholder proposal and nomination procedures.    | Management  | For  | For                    |
| 3.   | To approve an amendment to our Bye-laws to eliminate all supermajority voting requirements.          | Management  | For  | For                    |
| 4.   | To approve an amendment to our Bye-laws to modify certain director removal and vacancy requirements. | Management  | For  | For                    |
| 5.   | To approve an amendment to our Bye-laws to revise certain other provisions in our Bye-laws.          | Management  | For  | For                    |

**NATERA, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 632307104   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | NTRA        | <b>Meeting Date</b> | 16-May-2018 |
| <b>Record Date</b>   | 26-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                   | Proposed by | Vote | For/Against Management |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                   | Management  |      |                        |
|      | 1 Roelof F. Botha                                                                                                                                          |             | For  | For                    |
|      | 2 Todd Cozzens                                                                                                                                             |             | For  | For                    |
|      | 3 Matthew Rabinowitz                                                                                                                                       |             | For  | For                    |
| 2.   | Proposal to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**NEKTAR THERAPEUTICS**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 640268108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | NKTR        | <b>Meeting Date</b> | 26-Jun-2018 |
| <b>Record Date</b>   | 27-Apr-2018 |                     |             |

| Item | Proposal                               | Proposed by | Vote | For/Against Management |
|------|----------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Director: Jeff Ajer        | Management  | For  | For                    |
| 1b.  | Election of Director: Robert B. Chess  | Management  | For  | For                    |
| 1c.  | Election of Director: Roy A. Whitfield | Management  | For  | For                    |

## Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

|    |                                                                                                                                                                                                                                                                           |            |     |     |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| 2. | To approve an amendment and restatement of the 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the 2017 Performance Incentive Plan by 10,900,000 shares to a total reserve of 19,200,000 shares. | Management | For | For |
| 3. | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.                                                                                                                           | Management | For | For |
| 4. | To approve a non-binding advisory resolution regarding our executive compensation (a say-on-pay vote).                                                                                                                                                                    | Management | For | For |

---

**NEUROCRINE BIOSCIENCES, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 64125C109   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | NBIX        | <b>Meeting Date</b> | 24-May-2018 |
| <b>Record Date</b>   | 29-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                             | Proposed by | Vote    | For/Against Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                             | Management  |         |                        |
|      | 1 William H Rastetter PhD                                                                                                                                                            |             | For     | For                    |
|      | 2 George J. Morrow                                                                                                                                                                   |             | For     | For                    |
| 2.   | Advisory vote to approve the compensation paid to the Company's named executive officers.                                                                                            | Management  | For     | For                    |
| 3.   | To approve an amendment to the Company's 2011 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder from 17,000,000 to 19,000,000. | Management  | For     | For                    |
| 4.   | To approve the Company's 2018 Employee Stock Purchase Plan.                                                                                                                          | Management  | Against | Against                |
| 5.   | To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.                          | Management  | For     | For                    |

**NEVRO CORP.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 64157F103   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | NVRO        | <b>Meeting Date</b> | 21-May-2018 |
| <b>Record Date</b>   | 28-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                                   | Proposed by | Vote | For/Against Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                                                                   | Management  |      |                        |
|      | 1 Brad Vale, Ph.D., DVM                                                                                                                                                                                                                    |             | For  | For                    |
|      | 2 Michael DeMane                                                                                                                                                                                                                           |             | For  | For                    |
|      | 3 Lisa D. Earnhardt                                                                                                                                                                                                                        |             | For  | For                    |
| 2.   | To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018        | Management  | For  | For                    |
| 3.   | To approve, on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement in accordance with the compensation disclosure rules of the Securities and Exchange Commission | Management  | For  | For                    |

**NEWLINK GENETICS CORPORATION**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 651511107   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | NLNK        | <b>Meeting Date</b> | 23-May-2018 |
| <b>Record Date</b>   | 26-Mar-2018 |                     |             |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                                                                                                                                                                                 | Proposed by | Vote   | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                                 | Management  |        |                        |
|      | 1 Chad A. Johnson                                                                                                                                                                                        |             | For    | For                    |
|      | 2 Ernest J. Talarico, III                                                                                                                                                                                |             | For    | For                    |
|      | 3 Lota S. Zoth                                                                                                                                                                                           |             | For    | For                    |
| 2.   | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                       | Management  | For    | For                    |
| 3.   | To indicate, on an advisory basis, the preferred frequency of future advisory votes on the compensation of our named executive officers.                                                                 | Management  | 1 Year | For                    |
| 4.   | To ratify the selection, by the Audit Committee of the Board of Directors, of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. | Management  | For    | For                    |

**NUCANA PLC**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 67022C106   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | NCNA        | <b>Meeting Date</b> | 27-Jun-2018 |
| <b>Record Date</b>   | 24-May-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| O1   | To re-elect (as a Class III director) Isaac Cheng, who is retiring in accordance with the Articles of Association of the Company, as a director of the Company.                                                                                                                                                                                                                                                                                                                                                                                                             | Management  | For  | N/A                    |
| O2   | To re-elect (as a Class III director) Martin Mellish, who is retiring by rotation in accordance with the Articles of Association of the Company, as a director of the Company.                                                                                                                                                                                                                                                                                                                                                                                              | Management  | For  | N/A                    |
| O3   | To re-elect (as a Class III director) Adam George, who is retiring by rotation in accordance with the Articles of Association of the Company, as a director of the Company.                                                                                                                                                                                                                                                                                                                                                                                                 | Management  | For  | N/A                    |
| O4   | To elect (as a Class II director) Cyrille Leperlier, who is standing for election for the remaining portion of his term of office, as a director of the Company.                                                                                                                                                                                                                                                                                                                                                                                                            | Management  | For  | N/A                    |
| O5   | To re-appoint Ernst & Young LLP as auditors of the Company to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting of the Company.                                                                                                                                                                                                                                                                                                                                                                                       | Management  | For  | N/A                    |
| O6   | To authorise the directors to determine the remuneration of the auditors of the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Management  | For  | N/A                    |
| O7   | To receive the Company's audited accounts for the financial year ended 31 December 2017, together with the strategic report, directors' report and auditors' report on those accounts.                                                                                                                                                                                                                                                                                                                                                                                      | Management  | For  | N/A                    |
| O8   | To receive and approve the Directors' Remuneration Report (other than the part containing the Directors' Remuneration Policy) for the financial year ended 31 December 2017.                                                                                                                                                                                                                                                                                                                                                                                                | Management  | For  | N/A                    |
| O9   | To receive and approve the Directors' Remuneration Policy, such policy to take effect from the date on which this resolution is passed.                                                                                                                                                                                                                                                                                                                                                                                                                                     | Management  | For  | N/A                    |
| O10  | That the directors be generally and unconditionally authorised pursuant to Section 551 of the Companies Act 2006 (the "Act") to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of GBP 640,000. This authority shall, unless previously renewed, revoked or varied by the Company in general meeting, expire on the conclusion of the annual general meeting ...(due to space limits, see proxy material for full proposal). | Management  | For  | N/A                    |
| S11  | That, subject to the passing of resolution 10, the directors be empowered pursuant to Section 570 of the Act to allot equity securities (as defined in Section 560 of the Act) for cash under the authority given by that resolution as if Section 561 (1) of the Act did not apply to any such allotment, provided that such authority shall be limited to the allotment of equity securities up to a nominal amount of GBP 640,000, such authority to expire on the conclusion of the annual general ...(due to space limits, see proxy                                   | Management  | For  | N/A                    |



material for full proposal).

---

**OVID THERAPEUTICS INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 690469101   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | OVID        | <b>Meeting Date</b> | 06-Jun-2018 |
| <b>Record Date</b>   | 11-Apr-2018 |                     |             |

| Item | Proposal                                                                            | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                            | Management  |      |                        |
|      | 1 Douglas Williams                                                                  |             | For  | For                    |
|      | 2 Barbara Duncan                                                                    |             | For  | For                    |
| 2.   | Ratification of the selection of the independent registered public accounting firm. | Management  | For  | For                    |

**PFIZER INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 717081103   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | PFE         | <b>Meeting Date</b> | 26-Apr-2018 |
| <b>Record Date</b>   | 27-Feb-2018 |                     |             |

| Item | Proposal                                                                                   | Proposed by | Vote    | For/Against Management |
|------|--------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1a.  | Election of Director: Dennis A. Ausiello                                                   | Management  | For     | For                    |
| 1b.  | Election of Director: Ronald E. Blaylock                                                   | Management  | For     | For                    |
| 1c.  | Election of Director: Albert Bourla                                                        | Management  | For     | For                    |
| 1d.  | Election of Director: W. Don Cornwell                                                      | Management  | For     | For                    |
| 1e.  | Election of Director: Joseph J. Echevarria                                                 | Management  | For     | For                    |
| 1f.  | Election of Director: Helen H. Hobbs                                                       | Management  | For     | For                    |
| 1g.  | Election of Director: James M. Kilts                                                       | Management  | For     | For                    |
| 1h.  | Election of Director: Dan R. Littman                                                       | Management  | For     | For                    |
| 1i.  | Election of Director: Shantanu Narayan                                                     | Management  | For     | For                    |
| 1j.  | Election of Director: Suzanne Nora Johnson                                                 | Management  | For     | For                    |
| 1k.  | Election of Director: Ian C. Read                                                          | Management  | For     | For                    |
| 1l.  | Election of Director: James C. Smith                                                       | Management  | For     | For                    |
| 2.   | Ratify the selection of KPMG LLP as independent registered public accounting firm for 2018 | Management  | For     | For                    |
| 3.   | 2018 Advisory approval of executive compensation                                           | Management  | For     | For                    |
| 4.   | Approval of the Pfizer Inc. French Sub-Plan under the 2014 Stock Plan                      | Management  | For     | For                    |
| 5.   | Shareholder proposal regarding right to act by written consent                             | Shareholder | Against | For                    |
| 6.   | Shareholder proposal regarding independent chair policy                                    | Shareholder | Against | For                    |
| 7.   | Shareholder proposal regarding report on lobbying activities                               | Shareholder | Against | For                    |

**PIERIS PHARMACEUTICALS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 720795103   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | PIRS        | <b>Meeting Date</b> | 24-Jul-2018 |
| <b>Record Date</b>   | 25-May-2018 |                     |             |

| Item | Proposal                                                                                                                                                 | Proposed by | Vote | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                 | Management  |      |                        |
|      | 1 Christopher P. Kiritsy                                                                                                                                 |             | For  | For                    |
|      | 2 Jean-Pierre Bizzari                                                                                                                                    |             | For  | For                    |
| 2.   | Approve the Company's 2018 Employee, Director and Consultant Equity Incentive Plan.                                                                      | Management  | For  | For                    |
| 3.   | Approve the Company's 2018 Employee Stock Purchase Plan.                                                                                                 | Management  | For  | For                    |
| 4.   | Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**PORTOLA PHARMACEUTICALS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 737010108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | PTLA        | <b>Meeting Date</b> | 08-Jun-2018 |
| <b>Record Date</b>   | 12-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                    | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                                    | Management  |      |                        |
|      | 1 Dennis Fenton, Ph.D.                                                                                                                                                                                      |             | For  | For                    |
|      | 2 Charles Homcy, M.D.                                                                                                                                                                                       |             | For  | For                    |
|      | 3 David C. Stump, M.D.                                                                                                                                                                                      |             | For  | For                    |
| 2.   | To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 100,000,000 to 150,000,000 shares. | Management  | For  | For                    |
| 3.   | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.                                                                         | Management  | For  | For                    |
| 4.   | To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.                                                   | Management  | For  | For                    |

**PRA HEALTH SCIENCES, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 69354M108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | PRAH        | <b>Meeting Date</b> | 31-May-2018 |
| <b>Record Date</b>   | 05-Apr-2018 |                     |             |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                                                                                                    | Proposed<br>by | Vote | For/Against<br>Management |
|------|-----------------------------------------------------------------------------------------------------------------------------|----------------|------|---------------------------|
| 1.   | DIRECTOR                                                                                                                    | Management     |      |                           |
|      | 1 Max C. Lin                                                                                                                |                | For  | For                       |
|      | 2 Matthew P. Young                                                                                                          |                | For  | For                       |
| 2.   | To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for 2018. | Management     | For  | For                       |
| 3.   | Approval, in a non-binding advisory vote, of the compensation paid to the Company's named executive officers.               | Management     | For  | For                       |
| 4.   | Approval of the PRA Health Sciences, Inc. 2018 Stock Incentive Plan.                                                        | Management     | For  | For                       |

---

**PROTAGONIST THERAPEUTICS INC**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 74366E102   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | PTGX        | <b>Meeting Date</b> | 29-May-2018 |
| <b>Record Date</b>   | 09-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                          | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                                          | Management  |      |                        |
|      | 1 Chaitan Khosla, Ph.D.                                                                                                                                                                                           |             | For  | For                    |
|      | 2 William D. Waddill                                                                                                                                                                                              |             | For  | For                    |
|      | 3 Lewis T Williams MD PhD                                                                                                                                                                                         |             | For  | For                    |
| 2.   | To ratify the selection by the Audit Committee of the Board of PricewaterhouseCoopers LLP as Protagonist Therapeutics independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**PTC THERAPEUTICS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 69366J200   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | PTCT        | <b>Meeting Date</b> | 13-Jun-2018 |
| <b>Record Date</b>   | 20-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                          | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                          | Management  |      |                        |
|      | 1 Michael Schmertzler                                                                                                                                             |             | For  | For                    |
|      | 2 G D Steele Jr., MD, PhD                                                                                                                                         |             | For  | For                    |
| 2.   | Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |
| 3.   | Advisory vote to approve named executive officer compensation.                                                                                                    | Management  | For  | For                    |

**RA PHARMACEUTICALS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 74933V108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | RARX        | <b>Meeting Date</b> | 28-Jun-2018 |
| <b>Record Date</b>   | 30-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                    | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                    | Management  |      |                        |
|      | 1 Robert Heft, Ph.D.                                                                                                        |             | For  | For                    |
|      | 2 Rajeev Shah                                                                                                               |             | For  | For                    |
| 2.   | To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year | Management  | For  | For                    |

# Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

ending December 31, 2018.

## REGENERON PHARMACEUTICALS, INC.

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 75886F107   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | REGN        | <b>Meeting Date</b> | 08-Jun-2018 |
| <b>Record Date</b>   | 12-Apr-2018 |                     |             |

| <b>Item</b> | <b>Proposal</b>                                                                                                                                                            | <b>Proposed<br/>by</b> | <b>Vote</b> | <b>For/Against<br/>Management</b> |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-------------|-----------------------------------|
| 1.1         | Election of Director: Arthur F. Ryan                                                                                                                                       | Management             | For         | For                               |
| 1.2         | Election of Director: George L. Sing                                                                                                                                       | Management             | For         | For                               |
| 1.3         | Election of Director: Marc Tessier-Lavigne                                                                                                                                 | Management             | For         | For                               |
| 2.          | Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management             | For         | For                               |

---

**SAGE THERAPEUTICS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 78667J108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | SAGE        | <b>Meeting Date</b> | 06-Jun-2018 |
| <b>Record Date</b>   | 09-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                   | Proposed by  | Vote | For/Against Management |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                   | Management   |      |                        |
|      | 1                                                                                                                                                          | Geno Germano | For  | For                    |
|      | 2                                                                                                                                                          | Steven Paul  | For  | For                    |
| 2.   | To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management   | For  | For                    |
| 3.   | Approve, on an advisory basis, the compensation of the named executive officers.                                                                           | Management   | For  | For                    |

**SAREPTA THERAPEUTICS INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 803607100   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | SRPT        | <b>Meeting Date</b> | 06-Jun-2018 |
| <b>Record Date</b>   | 11-Apr-2018 |                     |             |

| Item | Proposal                                                                                                        | Proposed by | Vote | For/Against Management |
|------|-----------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1A   | ELECTION OF GROUP I DIRECTOR: Michael W. Bonney                                                                 | Management  | For  | For                    |
| 1B   | ELECTION OF GROUP I DIRECTOR: Douglas S. Ingram                                                                 | Management  | For  | For                    |
| 1C   | ELECTION OF GROUP I DIRECTOR: Hans Wigzell, M.D., Ph.D.                                                         | Management  | For  | For                    |
| 2.   | ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION                          | Management  | For  | For                    |
| 3.   | APPROVAL OF THE COMPANY S 2018 EQUITY INCENTIVE PLAN                                                            | Management  | For  | For                    |
| 4.   | RATIFICATION OF KPMG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2018 | Management  | For  | For                    |

**SEATTLE GENETICS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 812578102   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | SGEN        | <b>Meeting Date</b> | 18-May-2018 |
| <b>Record Date</b>   | 22-Mar-2018 |                     |             |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                                                                                                                                                                                                                                     | Proposed<br>by | Vote | For/Against<br>Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------|---------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                                                                                     | Management     |      |                           |
|      | 1 Clay B. Siegall                                                                                                                                                                                                                                            |                | For  | For                       |
|      | 2 Felix Baker                                                                                                                                                                                                                                                |                | For  | For                       |
|      | 3 Nancy A. Simonian                                                                                                                                                                                                                                          |                | For  | For                       |
| 2.   | To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.                                                                                         | Management     | For  | For                       |
| 3.   | To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity and Incentive Plan to, among other changes, increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000. | Management     | For  | For                       |
| 4.   | Advisory vote to approve the compensation of the Company's named executive officers as disclosed in the Company's proxy statement.                                                                                                                           | Management     | For  | For                       |



## SHIRE PLC

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 82481R106   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | SHPG        | <b>Meeting Date</b> | 24-Apr-2018 |
| <b>Record Date</b>   | 22-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | To receive the Company's Annual Report and Accounts for the year ended December 31, 2017.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Management  | For  | For                    |
| 2.   | To approve the Directors' Remuneration Report, excluding the Directors' Remuneration Policy, set out on pages 78 to 108 of the Annual Report and Accounts for the year ended December 31, 2017.                                                                                                                                                                                                                                                                                                                                                                           | Management  | For  | For                    |
| 3.   | To approve the Directors' Remuneration Policy, contained within the Directors' Remuneration Report and set out on pages 86 to 95 of the Annual Report and Accounts for the year ended December 31, 2017, to take effect after the end of the Annual General Meeting on April 24, 2018.                                                                                                                                                                                                                                                                                    | Management  | For  | For                    |
| 4.   | To re-elect Olivier Bohuon as a Director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Management  | For  | For                    |
| 5.   | To re-elect Ian Clark as a Director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Management  | For  | For                    |
| 6.   | To elect Thomas Dittrich as a Director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Management  | For  | For                    |
| 7.   | To re-elect Gail Fosler as a Director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Management  | For  | For                    |
| 8.   | To re-elect Steven Gillis as a Director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Management  | For  | For                    |
| 9.   | To re-elect David Ginsburg as a Director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Management  | For  | For                    |
| 10.  | To re-elect Susan Kilsby as a Director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Management  | For  | For                    |
| 11.  | To re-elect Sara Mathew as a Director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Management  | For  | For                    |
| 12.  | To re-elect Flemming Ornskov as a Director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Management  | For  | For                    |
| 13.  | To re-elect Albert Stroucken as a Director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Management  | For  | For                    |
| 14.  | To re-appoint Deloitte LLP as the Company's Auditor until the conclusion of the next Annual General Meeting of the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                               | Management  | For  | For                    |
| 15.  | To authorize the Audit, Compliance & Risk Committee to determine the remuneration of the Auditor.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Management  | For  | For                    |
| 16.  | That the authority to allot Relevant Securities (as defined in the Company's Articles of Association (the "Articles")) conferred on the Directors by Article 10 paragraph (B) of the Articles be renewed and for this purpose the Authorised Allotment Amount shall be: (a) GBP 15,187,600.85 of Relevant Securities. (b) solely in connection with an allotment pursuant to an offer by way of a Rights Issue (as defined in the Articles, but only if and to the extent that such offer is ... (due to space limits, see proxy material for full proposal).             | Management  | For  | For                    |
| 17.  | That, subject to the passing of Resolution 16, the authority to allot equity securities (as defined in the Company's Articles of Association (the "Articles")) wholly for cash conferred on the Directors by Article 10 paragraph (D) of the Articles be renewed and for this purpose the Non Pre-emptive Amount (as defined in the Articles) shall be GBP 2,278,140.10 and the Allotment Period shall be the period commencing on April 24, 2018, and ending on the earlier of the close of business on ... (due to space limits, see proxy material for full proposal). | Management  | For  | For                    |
| 18.  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Management  | For  | For                    |

# Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

That, subject to the passing of Resolutions 16 and 17 and for the purpose of the authority to allot equity securities (as defined in the Company's Articles of Association (the Articles)) wholly for cash conferred on the Directors by Article 10 paragraph (D) of the Articles and renewed by Resolution 17, the Non Pre-emptive Amount (as defined in the Articles) shall be increased from GBP 2,278,140.10 to GBP ...(due to space limits, see proxy material for full proposal).

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |     |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| 19. | That the Company be and is hereby generally and unconditionally authorized: (a) pursuant to Article 57 of the Companies (Jersey) Law 1991 to make market purchases of Ordinary Shares in the capital of the Company, provided that: (1) the maximum number of Ordinary Shares hereby authorized to be purchased is 91,125,605; (2) the minimum price, exclusive of any expenses, which may be paid for an Ordinary Share is five pence; (3) the maximum price, exclusive of any expenses, which may be paid ...(due to space limits, see proxy material for full proposal). | Management | For | For |
| 20. | To approve that a general meeting of the Company, other than an annual general meeting, may be called on not less than 14 clear days' notice.                                                                                                                                                                                                                                                                                                                                                                                                                               | Management | For | For |

**TELIGENT, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 87960W104   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | TLGT        | <b>Meeting Date</b> | 21-May-2018 |
| <b>Record Date</b>   | 29-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                                      | Proposed by             | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                                      | Management              |      |                        |
|      | 1                                                                                                                                                                                                             | Carole S. Ben-Maimon    | For  | For                    |
|      | 2                                                                                                                                                                                                             | John Celentano          | For  | For                    |
|      | 3                                                                                                                                                                                                             | Bhaskar Chaudhuri       | For  | For                    |
|      | 4                                                                                                                                                                                                             | James C. Gale           | For  | For                    |
|      | 5                                                                                                                                                                                                             | Jason Grenfell-Gardner  | For  | For                    |
|      | 6                                                                                                                                                                                                             | Steven Koehler          | For  | For                    |
|      | 7                                                                                                                                                                                                             | Thomas J. Sabatino, Jr. | For  | For                    |
| 2.   | Approve an amendment to the Teligent, Inc. 2016 Equity Incentive Plan to increase the number of shares of common stock reserved thereunder for issuance from 2,000,000 shares to a total of 4,000,000 shares. | Management              | For  | For                    |
| 3.   | To ratify the selection of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.                                                       | Management              | For  | For                    |
| 4.   | To approve by an advisory vote the compensation of the Company's named executive officers as disclosed in the proxy statement.                                                                                | Management              | For  | For                    |

**TESARO INC**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 881569107   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | TSRO        | <b>Meeting Date</b> | 10-May-2018 |
| <b>Record Date</b>   | 13-Mar-2018 |                     |             |

| Item | Proposal                                                                                                         | Proposed by             | Vote | For/Against Management |
|------|------------------------------------------------------------------------------------------------------------------|-------------------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                         | Management              |      |                        |
|      | 1                                                                                                                | Leon O. Moulder, Jr.    | For  | For                    |
|      | 2                                                                                                                | Mary Lynne Hedley, Ph.D | For  | For                    |
|      | 3                                                                                                                | David M. Mott           | For  | For                    |
|      | 4                                                                                                                | Lawrence M. Alleva      | For  | For                    |
|      | 5                                                                                                                | James O. Armitage, M.D. | For  | For                    |
|      | 6                                                                                                                | Earl M. Collier, Jr.    | For  | For                    |
|      | 7                                                                                                                | Garry A. Nicholson      | For  | For                    |
|      | 8                                                                                                                | Kavita Patel, M.D.      | For  | For                    |
|      | 9                                                                                                                | Beth Seidenberg, M.D.   | For  | For                    |
|      | 10                                                                                                               | Pascale Witz            | For  | For                    |
| 2.   | To approve the Tesaro, Inc., Non-Employee Director Compensation Policy, including compensation amounts for 2018. | Management              | For  | For                    |
| 3.   | To approve, by non-binding vote, the Company's executive compensation.                                           | Management              | For  | For                    |
| 4.   |                                                                                                                  | Management              | For  | For                    |

## Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

To approve an amendment to the Tesaro, Inc., 2012 Employee Stock Purchase Plan to, among other things, increase the number of shares available for issuance thereunder by 275,000 shares.

|    |                                                                                                                                                                    |            |     |     |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| 5. | To ratify the appointment of Ernst & Young, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018. | Management | For | For |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|

---

**TETRAPHASE PHARMACEUTICALS, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 88165N105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | TTPH        | <b>Meeting Date</b> | 30-May-2018 |
| <b>Record Date</b>   | 06-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                          | Proposed by | Vote | For/Against Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                          | Management  |      |                        |
|      | 1 Jeffrey Chodakewitz                                                                                                                             |             | For  | For                    |
|      | 2 Gerri Henwood                                                                                                                                   |             | For  | For                    |
|      | 3 Guy Macdonald                                                                                                                                   |             | For  | For                    |
| 2.   | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |
| 3.   | To approve, on a non-binding advisory basis, the compensation of our named executive officers.                                                    | Management  | For  | For                    |

**TEVA PHARMACEUTICAL INDUSTRIES LIMITED**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 881624209   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | TEVA        | <b>Meeting Date</b> | 05-Jun-2018 |
| <b>Record Date</b>   | 26-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                        | Proposed by | Vote   | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------|------------------------|
| 1.1  | Election of Director: Rosemary A. Crane                                                                                                                                                         | Management  | For    | For                    |
| 1.2  | Election of Director: Gerald M. Lieberman                                                                                                                                                       | Management  | For    | For                    |
| 1.3  | Election of Director: Professor Ronit Satchi-Fainaro                                                                                                                                            | Management  | For    | For                    |
| 2.   | To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers.                                                                                              | Management  | For    | For                    |
| 3.   | To recommend, on a non-binding advisory basis, to hold a non-binding advisory vote to approve the compensation for Teva's named executive officers every one, two or three years.               | Management  | 1 Year | For                    |
| 4.   | To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until the 2019 annual meeting of shareholders. | Management  | For    | For                    |
| 5.   | To approve an amendment and restatement of Teva's 2008 Employee Stock Purchase Plan for U.S. Employees.                                                                                         | Management  | For    | For                    |

**THE MEDICINES COMPANY**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 584688105   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | MDCO        | <b>Meeting Date</b> | 31-May-2018 |
| <b>Record Date</b>   | 13-Apr-2018 |                     |             |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                                                                                                                                                    | Proposed<br>by | Vote | For/Against<br>Management |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------|---------------------------|
| 1A.  | Election of Director: Alexander J. Denner                                                                                                                                   | Management     | For  | For                       |
| 1B.  | Election of Director: Fredric N. Eshelman                                                                                                                                   | Management     | For  | For                       |
| 1C.  | Election of Director: Geno J. Germano                                                                                                                                       | Management     | For  | For                       |
| 1D.  | Election of Director: John C. Kelly                                                                                                                                         | Management     | For  | For                       |
| 1E.  | Election of Director: Clive A. Meanwell                                                                                                                                     | Management     | For  | For                       |
| 1F.  | Election of Director: Paris Panayiotopoulos                                                                                                                                 | Management     | For  | For                       |
| 1G.  | Election of Director: Sarah J. Schlesinger                                                                                                                                  | Management     | For  | For                       |
| 2.   | Approve an amendment to our 2013 stock incentive plan in order to increase the number of shares of common stock authorized for issuance under the plan by 5,000,000 shares. | Management     | For  | For                       |
| 3.   | Approve, in an advisory vote, the compensation of our named executive officers as presented in the proxy statement.                                                         | Management     | For  | For                       |
| 4.   | Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.                              | Management     | For  | For                       |

---

**THERAPEUTICSMD, INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 88338N107   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | TXMD        | <b>Meeting Date</b> | 25-Jun-2018 |
| <b>Record Date</b>   | 26-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                                                   | Proposed by | Vote | For/Against Management |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1.   | DIRECTOR                                                                                                                                                                                   | Management  |      |                        |
|      | 1 Tommy G. Thompson                                                                                                                                                                        |             | For  | For                    |
|      | 2 Robert G. Finizio                                                                                                                                                                        |             | For  | For                    |
|      | 3 John C.K. Milligan, IV                                                                                                                                                                   |             | For  | For                    |
|      | 4 Brian Bernick                                                                                                                                                                            |             | For  | For                    |
|      | 5 J. Martin Carroll                                                                                                                                                                        |             | For  | For                    |
|      | 6 Cooper C. Collins                                                                                                                                                                        |             | For  | For                    |
|      | 7 Robert V. LaPenta, Jr.                                                                                                                                                                   |             | For  | For                    |
|      | 8 Jules A. Musing                                                                                                                                                                          |             | For  | For                    |
|      | 9 Angus C. Russell                                                                                                                                                                         |             | For  | For                    |
|      | 10 Jane F. Barlow                                                                                                                                                                          |             | For  | For                    |
|      | 11 Nicholas Segal                                                                                                                                                                          |             | For  | For                    |
| 2.   | To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2017 (say-on-pay).                                    | Management  | For  | For                    |
| 3.   | To ratify the appointment of Grant Thornton LLP, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2018. | Management  | For  | For                    |

**THERMO FISHER SCIENTIFIC INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 883556102   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | TMO         | <b>Meeting Date</b> | 23-May-2018 |
| <b>Record Date</b>   | 28-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                      | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1A.  | Election of Director: Marc N. Casper                                                                                          | Management  | For  | For                    |
| 1B.  | Election of Director: Nelson J. Chai                                                                                          | Management  | For  | For                    |
| 1C.  | Election of Director: C. Martin Harris                                                                                        | Management  | For  | For                    |
| 1D.  | Election of Director: Tyler Jacks                                                                                             | Management  | For  | For                    |
| 1E.  | Election of Director: Judy C. Lewent                                                                                          | Management  | For  | For                    |
| 1F.  | Election of Director: Thomas J. Lynch                                                                                         | Management  | For  | For                    |
| 1G.  | Election of Director: Jim P. Manzi                                                                                            | Management  | For  | For                    |
| 1H.  | Election of Director: Lars R. Sorensen                                                                                        | Management  | For  | For                    |
| 1I.  | Election of Director: Scott M. Sperling                                                                                       | Management  | For  | For                    |
| 1J.  | Election of Director: Elaine S. Ullian                                                                                        | Management  | For  | For                    |
| 1K.  | Election of Director: Dion J. Weisler                                                                                         | Management  | For  | For                    |
| 2.   | An advisory vote to approve named executive officer compensation.                                                             | Management  | For  | For                    |
| 3.   | Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2018. | Management  | For  | For                    |

**THEROX, INC.**

|                      |     |                     |                 |
|----------------------|-----|---------------------|-----------------|
| <b>Security</b>      | N/A | <b>Meeting Type</b> | Written Consent |
| <b>Ticker Symbol</b> | N/A | <b>Meeting Date</b> | 24-Apr-2018     |
| <b>Record Date</b>   | N/A |                     |                 |

| Item | Proposal                                                                                                  | Proposed<br>by | Vote    | For/Against<br>Management |
|------|-----------------------------------------------------------------------------------------------------------|----------------|---------|---------------------------|
| 1.   | Approval of Second Certificate of Amendment to Eleventh Amended and Restated Certificate of Incorporation | Management     | For     | For                       |
| 2.   | Waiver of Participation Rights in Note Transaction                                                        | Management     | For     | For                       |
| 3.   | Approval of Amendment to Fourth Amended and Restated Investors Rights and Voting Agreement                | Management     | For     | For                       |
| 4.   | Approval of Option Agreement with ZOLL                                                                    | Management     | For     | For                       |
| 5.   | Approval of Agreement and Plan of Merger                                                                  | Management     | For     | For                       |
| 6.   | Appointment of Shareholder Representative Services, LLC as Representative                                 | Management     | For     | For                       |
| 7.   | Appointment of Representative Advisory Group Members                                                      | Shareholder    | Against | For                       |
| 8.   | Ratification of Shadow Preferred Stock Issuance                                                           | Shareholder    | Against | For                       |
| 9.   | General Authority                                                                                         | Shareholder    | Against | For                       |

---



Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

**TRILLIUM THERAPEUTICS INC.**

|                      |             |                     |                            |
|----------------------|-------------|---------------------|----------------------------|
| <b>Security</b>      | 89620X506   | <b>Meeting Type</b> | Annual and Special Meeting |
| <b>Ticker Symbol</b> | TRIL        | <b>Meeting Date</b> | 01-Jun-2018                |
| <b>Record Date</b>   | 20-Apr-2018 |                     |                            |

| Item | Proposal                                                                                                                                                                                                                                 | Proposed by             | Vote    | For/Against Management |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|---------|------------------------|
| 1    | DIRECTOR                                                                                                                                                                                                                                 | Management              |         |                        |
|      | 1                                                                                                                                                                                                                                        | Mr. Luke Beshar         | For     | For                    |
|      | 2                                                                                                                                                                                                                                        | Dr. Robert Kirkman      | For     | For                    |
|      | 3                                                                                                                                                                                                                                        | Dr. Michael Moore       | For     | For                    |
|      | 4                                                                                                                                                                                                                                        | Dr. Thomas Reynolds     | For     | For                    |
|      | 5                                                                                                                                                                                                                                        | Dr. Niclas Stiernholm   | For     | For                    |
|      | 6                                                                                                                                                                                                                                        | Dr. Calvin Stiller      | For     | For                    |
|      | 7                                                                                                                                                                                                                                        | Dr. Helen Tayton-Martin | For     | For                    |
| 2    | To reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors. | Management              | For     | For                    |
| 3    | Consider and, if deemed appropriate, approve the Corporation's amended and restated stock option plan, all as more particularly set out in the management information circular prepared by the Corporation in respect of the Meeting.    | Management              | Against | Against                |

**ULTRAGENYX PHARMACEUTICAL INC.**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 90400D108   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | RARE        | <b>Meeting Date</b> | 19-Jun-2018 |
| <b>Record Date</b>   | 23-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                              | Proposed by | Vote | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Director: Deborah Dunsire, M.D.                                                                                                           | Management  | For  | For                    |
| 1b.  | Election of Director: Michael Narachi                                                                                                                 | Management  | For  | For                    |
| 1c.  | Election of Director: Clay B. Siegall, Ph.D.                                                                                                          | Management  | For  | For                    |
| 2.   | Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. | Management  | For  | For                    |
| 3.   | Advisory (non-binding) vote to approve the compensation of our named executive officers.                                                              | Management  | For  | For                    |

**UNITED THERAPEUTICS CORPORATION**

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 91307C102   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | UTHR        | <b>Meeting Date</b> | 26-Jun-2018 |
| <b>Record Date</b>   | 30-Apr-2018 |                     |             |

Edgar Filing: TEKLA HEALTHCARE INVESTORS - Form N-PX

| Item | Proposal                                                                                                                                          | Proposed<br>by | Vote | For/Against<br>Management |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------|---------------------------|
| 1a.  | Election of Director: Katherine Klein                                                                                                             | Management     | For  | For                       |
| 1b.  | Election of Director: Ray Kurzweil                                                                                                                | Management     | For  | For                       |
| 1c.  | Election of Director: Martine Rothblatt                                                                                                           | Management     | For  | For                       |
| 1d.  | Election of Director: Louis Sullivan                                                                                                              | Management     | For  | For                       |
| 2.   | Advisory resolution to approve executive compensation.                                                                                            | Management     | For  | For                       |
| 3.   | Approval of the amendment and restatement of the United Therapeutics Corporation 2015 Stock Incentive Plan.                                       | Management     | For  | For                       |
| 4.   | Ratification of the appointment of Ernst & Young LLP as United Therapeutics Corporation's independent registered public accounting firm for 2018. | Management     | For  | For                       |

---

## UNITEDHEALTH GROUP INCORPORATED

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 91324P102   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | UNH         | <b>Meeting Date</b> | 04-Jun-2018 |
| <b>Record Date</b>   | 10-Apr-2018 |                     |             |

| Item | Proposal                                                                                                                                                             | Proposed by | Vote | For/Against Management |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------|------------------------|
| 1a.  | Election of Director: William C. Ballard, Jr.                                                                                                                        | Management  | For  | For                    |
| 1b.  | Election of Director: Richard T. Burke                                                                                                                               | Management  | For  | For                    |
| 1c.  | Election of Director: Timothy P. Flynn                                                                                                                               | Management  | For  | For                    |
| 1d.  | Election of Director: Stephen J. Hemsley                                                                                                                             | Management  | For  | For                    |
| 1e.  | Election of Director: Michele J. Hooper                                                                                                                              | Management  | For  | For                    |
| 1f.  | Election of Director: F. William McNabb III                                                                                                                          | Management  | For  | For                    |
| 1g.  | Election of Director: Valerie C. Montgomery Rice, M.D.                                                                                                               | Management  | For  | For                    |
| 1h.  | Election of Director: Glenn M. Renwick                                                                                                                               | Management  | For  | For                    |
| 1i.  | Election of Director: Kenneth I. Shine, M.D.                                                                                                                         | Management  | For  | For                    |
| 1j.  | Election of Director: David S. Wichmann                                                                                                                              | Management  | For  | For                    |
| 1k.  | Election of Director: Gail R. Wilensky, Ph.D.                                                                                                                        | Management  | For  | For                    |
| 2.   | Advisory approval of the Company's executive compensation.                                                                                                           | Management  | For  | For                    |
| 3.   | Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2018. | Management  | For  | For                    |

## VERTEX PHARMACEUTICALS INCORPORATED

|                      |             |                     |             |
|----------------------|-------------|---------------------|-------------|
| <b>Security</b>      | 92532F100   | <b>Meeting Type</b> | Annual      |
| <b>Ticker Symbol</b> | VRTX        | <b>Meeting Date</b> | 17-May-2018 |
| <b>Record Date</b>   | 29-Mar-2018 |                     |             |

| Item | Proposal                                                                                                                                                          | Proposed by | Vote    | For/Against Management |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------|------------------------|
| 1.1  | Election of Class I Director: Sangeeta N. Bhatia                                                                                                                  | Management  | For     | For                    |
| 1.2  | Election of Class I Director: Jeffrey M. Leiden                                                                                                                   | Management  | For     | For                    |
| 1.3  | Election of Class I Director: Bruce I. Sachs                                                                                                                      | Management  | For     | For                    |
| 2.   | Amendments to our charter and by-laws to eliminate supermajority provisions.                                                                                      | Management  | For     | For                    |
| 3.   | Amendment and restatement of our 2013 Stock and Option Plan, to among other things, increase the number of shares available under the plan by 8.0 million shares. | Management  | For     | For                    |
| 4.   | Ratification of Ernst & Young LLP as our Independent Registered Public Accounting firm for the year ending December 31, 2018.                                     | Management  | For     | For                    |
| 5.   | Advisory vote on named executive officer compensation.                                                                                                            | Management  | For     | For                    |
| 6.   | Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on the risks to us of rising drug prices.                         | Shareholder | Against | For                    |
| 7.   | Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on our policies and activities with respect to lobbying.          | Shareholder | Against | For                    |



**SIGNATURES**

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)                      Tekla Healthcare Investors

By (Signature and Title)\*

/s/ Daniel R. Omstead  
(Daniel R. Omstead, President)

Date                                      8/20/18

\_\_\_\_\_  
\*Print the name and title of each signing officer under his or her signature.